<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T06:54:40Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4303324" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4303324</identifier>
        <datestamp>2015-11-24</datestamp>
        <setSpec>acssd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" xml:lang="EN">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Chem Res Toxicol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Chem. Res. Toxicol</journal-id>
              <journal-id journal-id-type="publisher-id">tx</journal-id>
              <journal-id journal-id-type="coden">crtoec</journal-id>
              <journal-title-group>
                <journal-title>Chemical Research in Toxicology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0893-228X</issn>
              <issn pub-type="epub">1520-5010</issn>
              <publisher>
                <publisher-name>American Chemical
Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4303324</article-id>
              <article-id pub-id-type="pmcid">PMC4303324</article-id>
              <article-id pub-id-type="pmc-uid">4303324</article-id>
              <article-id pub-id-type="pmid">25418912</article-id>
              <article-id pub-id-type="doi">10.1021/tx5003996</article-id>
              <article-categories>
                <subj-group>
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Human <italic>in Vivo</italic> Pharmacokinetics of
[<sup>14</sup>C]Dibenzo[<italic>def,p</italic>]chrysene by Accelerator
Mass Spectrometry Following Oral Microdosing</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="ath1">
                  <name>
                    <surname>Madeen</surname>
                    <given-names>Erin</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">†</xref>
                  <xref rid="aff1" ref-type="aff">‡</xref>
                </contrib>
                <contrib contrib-type="author" id="ath2">
                  <name>
                    <surname>Corley</surname>
                    <given-names>Richard A.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">‡</xref>
                  <xref rid="aff3" ref-type="aff">⊥</xref>
                </contrib>
                <contrib contrib-type="author" id="ath3">
                  <name>
                    <surname>Crowell</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">‡</xref>
                  <xref rid="aff3" ref-type="aff">⊥</xref>
                </contrib>
                <contrib contrib-type="author" id="ath4">
                  <name>
                    <surname>Turteltaub</surname>
                    <given-names>Kenneth</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">#</xref>
                </contrib>
                <contrib contrib-type="author" id="ath5">
                  <name>
                    <surname>Ognibene</surname>
                    <given-names>Ted</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">¶</xref>
                </contrib>
                <contrib contrib-type="author" id="ath6">
                  <name>
                    <surname>Malfatti</surname>
                    <given-names>Mike</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">#</xref>
                </contrib>
                <contrib contrib-type="author" id="ath7">
                  <name>
                    <surname>McQuistan</surname>
                    <given-names>Tammie
J.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">§</xref>
                </contrib>
                <contrib contrib-type="author" id="ath8">
                  <name>
                    <surname>Garrard</surname>
                    <given-names>Mary</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">‡</xref>
                  <xref rid="aff1" ref-type="aff">§</xref>
                  <xref rid="aff1" ref-type="aff">∥</xref>
                </contrib>
                <contrib contrib-type="author" id="ath9">
                  <name>
                    <surname>Sudakin</surname>
                    <given-names>Dan</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">†</xref>
                  <xref rid="aff1" ref-type="aff">‡</xref>
                  <xref rid="aff1" ref-type="aff">∥</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes" id="ath10">
                  <name>
                    <surname>Williams</surname>
                    <given-names>David E.</given-names>
                  </name>
                  <xref rid="cor1" ref-type="other">*</xref>
                  <xref rid="aff1" ref-type="aff">†</xref>
                  <xref rid="aff1" ref-type="aff">‡</xref>
                  <xref rid="aff1" ref-type="aff">§</xref>
                  <xref rid="aff1" ref-type="aff">∥</xref>
                </contrib>
                <aff id="aff1"><sup>†</sup>Department of Environmental and Molecular Toxicology, <sup>‡</sup>Superfund Research
Center, <sup>§</sup>Linus Pauling Institute, and <sup>∥</sup>Environmental Health Sciences Center, <institution>Oregon State University</institution>, Corvallis, Oregon 97331, <country>United States</country></aff>
                <aff id="aff3"><label>⊥</label>Systems
Toxicology &amp; Exposure Science, <institution>Pacific
Northwest National Laboratory</institution>, Richland, Washington 99354, <country>United States</country></aff>
                <aff id="aff4"><label>#</label>Biology and
Biotechnology Research Division, and <sup>¶</sup>the Center for Accelerator Mass Spectrometry, <institution>Lawrence Livermore National Laboratory</institution>, Livermore, California 94550, <country>United States</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>*</label>Phone: <phone>541-737-3277</phone>. E-mail: <email>david.williams@oregonstate.edu</email>.</corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>24</day>
                <month>11</month>
                <year>2015</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>11</month>
                <year>2014</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>20</day>
                <month>01</month>
                <year>2015</year>
              </pub-date>
              <volume>28</volume>
              <issue>1</issue>
              <fpage>126</fpage>
              <lpage>134</lpage>
              <history>
                <date date-type="received">
                  <day>29</day>
                  <month>09</month>
                  <year>2014</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2014 American Chemical
Society</copyright-statement>
                <copyright-year>2014</copyright-year>
                <copyright-holder>American Chemical
Society</copyright-holder>
                <license>
                  <license-p>This is an open access article published under an ACS AuthorChoice <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">License</ext-link>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.</license-p>
                </license>
              </permissions>
              <abstract>
                <p content-type="toc-graphic">
                  <graphic xlink:href="tx-2014-003996_0006" id="ab-tgr1"/>
                </p>
                <p>Dibenzo(<italic>def,p</italic>)chrysene
(DBC), (also known as dibenzo[<italic>a,l</italic>]pyrene), is a high
molecular weight polycyclic aromatic
hydrocarbon (PAH) found in the environment, including food, produced
by the incomplete combustion of hydrocarbons. DBC, classified by IARC
as a 2A probable human carcinogen, has a relative potency factor (RPF)
in animal cancer models 30-fold higher than benzo[<italic>a</italic>]pyrene. No data are available describing the disposition of high
molecular weight (&gt;4 rings) PAHs in humans to compare to animal
studies.
Pharmacokinetics of DBC was determined in 3 female and 6 male human
volunteers following oral microdosing (29 ng, 5 nCi) of [<sup>14</sup>C]-DBC. This study was made possible with highly sensitive accelerator
mass spectrometry (AMS), capable of detecting [<sup>14</sup>C]-DBC
equivalents in plasma and urine following a dose considered of <italic>de minimus</italic> risk to human health. Plasma and urine were collected
over 72 h. The plasma <italic>C</italic><sub>max</sub> was 68.8 ±
44.3 fg·mL<sup>–1</sup> with a <italic>T</italic><sub>max</sub> of 2.25 ± 1.04 h. Elimination occurred in two distinct
phases: a rapid (α)-phase, with a <italic>T</italic><sub>1/2</sub> of 5.8 ± 3.4 h and an apparent elimination rate constant (<italic>K</italic><sub>el</sub>) of 0.17 ± 0.12 fg·h<sup>–1</sup>, followed by a slower (β)-phase, with a <italic>T</italic><sub>1/2</sub> of 41.3 ± 29.8 h and an apparent <italic>K</italic><sub>el</sub> of 0.03 ± 0.02 fg·h<sup>–1</sup>.
In spite of the high degree of hydrophobicity (log <italic>K</italic><sub>ow</sub> of 7.4), DBC was eliminated rapidly in humans, as are
most PAHs in animals, compared to other hydrophobic persistent organic
pollutants such as, DDT, PCBs and TCDD. Preliminary examination utilizing
a new UHPLC-AMS interface, suggests the presence of polar metabolites
in plasma as early as 45 min following dosing. This is the first <italic>in vivo</italic> data set describing pharmacokinetics in humans of
a high molecular weight PAH and should be a valuable addition to risk
assessment paradigms.</p>
              </abstract>
              <funding-group>
                <funding-statement>
                  <funding-source>National Institutes of Health, United States</funding-source>
                </funding-statement>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>document-id-old-9</meta-name>
                  <meta-value>tx5003996</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>document-id-new-14</meta-name>
                  <meta-value>tx-2014-003996</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>ccc-price</meta-name>
                  <meta-value/>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1">
              <title>Introduction</title>
              <p>Polycyclic aromatic hydrocarbons (PAHs)
are produced by the incomplete
combustion of carbon and are of concern as environmental toxicants/carcinogens.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> The most recent list of the priority chemicals
at remediation sites by the Agency for Toxic Substances Disease Registry
(ATSDR) includes individual PAHs or PAH mixtures as three of the top
10 chemicals of concern.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Major sources
of environmental exposure include wood smoke, creosote, and burning
of fossil fuels and tobacco.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> PAHs consisting
of four rings or less constitute the low molecular weight, volatile
class. These PAHs tend to be less toxic and are typically classified
as level 3 or insufficient weight of evidence as carcinogens in humans.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> The major route of exposure to low molecular
weight PAHs, such as naphthalene, pyrene, and phenanthrene, is inhalation.
The high molecular weight PAHs include five or more aromatic rings.
The majority of exposure (&gt;95%), to high molecular weight PAHs
in
nonsmokers, is through the diet in a variety of foods including breads
and cereal grains, vegetables, and smoke-cured or barbequed meats.<sup><xref ref-type="bibr" rid="ref3">3</xref>−<xref ref-type="bibr" rid="ref5">5</xref></sup> The high molecular weight group contains the majority of the carcinogenic
PAHs, including benzo[<italic>a</italic>]pyrene (BaP, class 1, known
human carcinogen) and dibenzo[<italic>def,p</italic>]chrysene (DBC,
CAS 191-30-0, class 2A, probable human carcinogen).<sup><xref ref-type="bibr" rid="ref1">1</xref></sup></p>
              <p>Dietary intake of total PAHs in the U.S. has been
estimated to
be between 160 and 1600 ng/day.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Some studies
have reported intake levels of BaP alone at 40–2800 ng/day.<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref8">8</xref></sup> A 2005 report from the FAO/WHO Joint Expert Committee on Food Additives
and Contaminants listed a mean BaP daily dietary intake of 280 ng
per 70 kg individual with 700 ng considered as a high-level intake.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> Finally, a report by Menzie et al. estimated
total carcinogenic PAH intake at 3120 ng/day for a nonsmoking male,
19–50 years of age, of which 96.2% was from the diet.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> The European Union established a maximum limit
for BaP in smoked meats at 5,000 ng/kg fresh weight.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Data on DBC contamination of food is scarce. Veyrand et
al. addressed DBC (also known as dibenzo[<italic>a,l</italic>]pyrene)
as a component of food from a French market, estimating a daily exposure
of 0.129 ng/kg BW in French adults and 0.208 ng/kg BW in French children.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup></p>
              <p>Crowell et al. developed a physiologically
based pharmacokinetic
(PBPK) model for DBC and BaP, relying upon previous studies of <italic>in vitro</italic> (human and rodent liver) BaP metabolism and the
metabolic profile <italic>in vivo</italic> following oral gavage in
rodents.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Administering an oral dose of
15 mg/kg DBC to mice resulted in a <italic>T</italic><sub>max</sub> between 2 and 4 h, with detectable DBC in blood 48 h post gavage.
The <italic>T</italic><sub>1/2</sub> was found to be between 3.4 and
4.8 h.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup> The higher log <italic>K</italic><sub>ow</sub> of DBC (7.4), compared to that of BaP (6.1), is believed to contribute
to a prolonged sequestration in blood and other tissues. The DBC model
development relied heavily upon BaP due, in part, to the lack of available
data on DBC metabolism.</p>
              <p>Accelerator mass spectrometry (AMS)
measures the ratio of <sup>14</sup>C/C with <sup>14</sup>C detection
limits in the attomole
range per mg total carbon,<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> allowing the use of
a “microdose”, defined as a dose at least 2 orders of
magnitude below that which would be expected to yield a pharmacological
effect. AMS is increasingly being utilized by pharmaceutical companies
to assess pharmacokinetic parameters, metabolism, and excretion in
humans during drug development (Phase 0 trials).<sup><xref ref-type="bibr" rid="ref16">16</xref>−<xref ref-type="bibr" rid="ref18">18</xref></sup> These studies
almost exclusively utilized <sup>14</sup>C as the radiolabel, and
doses of 100 μCi have been standard.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> AMS is an attractive method to determine human pharmacokinetics,
DNA binding, and other potential biomarkers of importance in risk
assessment of compounds with potential toxicity. For example, AMS
has been utilized to determine DNA binding of [<sup>14</sup>C]- labeled
amino acid pyrolysis products or cooked meat mutagens, MeIQ, PhIP,
MeIQx,<sup><xref ref-type="bibr" rid="ref19">19</xref>−<xref ref-type="bibr" rid="ref22">22</xref></sup> as well as BaP<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> and the pharmacokinetics
of the potent human dietary hepatocarcinogen, aflatoxin B<sub>1</sub>.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> The sensitivity provided by AMS allows
for safe microdosing of human volunteers with chemical carcinogens,
such as DBC, at environmentally relevant doses, providing pharmacokinetic
parameters for risk assessment that do not rely solely on high-dose
animal studies.</p>
              <p>In this study, we determined the human <italic>in vivo</italic> pharmacokinetics of DBC, following microdosing,
utilizing AMS. Total
elimination of DBC<sub>eq</sub> (parent and metabolites), detected
as [<sup>14</sup>C], are used to determine the pharmacokinetics in
plasma and urine. Solid sample AMS is not able to distinguish between
labeled parent compound and metabolites. Total plasma distribution
and urinary elimination are compared to total plasma distribution
and urinary elimination scaled from rodent models.</p>
            </sec>
            <sec sec-type="methods" id="sec2">
              <title>Experimental Procedures</title>
              <sec id="sec2.1">
                <title>Human Volunteers</title>
                <p>All protocols and
procedures, including
plans for recruitment and volunteer informed consent documents, were
approved by the OSU Institutional Review Board. The use of radioisotopes
was reviewed and approved by an OSU Radioactive Use Agreement under
the oversight of the Oregon Health Authority. Healthy adult males
and infertile (postmenopausal or tubally ligated) females, between
the ages of 20–65, were recruited for this study. To protect
confidentiality, all specimens were deidentified at the time of collection.</p>
                <p>Additional inclusion criteria were as follows: good general health;
nonsmoking; not using medications that can affect gut motility; and
no history of gastrointestinal surgeries, kidney or liver disease,
gastrointestinal diseases such as Crohn’s, ulcerative colitis,
or gastritis. A medical examination was conducted by a licensed physician.
The screening assessment included a careful menopausal history and
a urine pregnancy test for all women. Women who were pregnant or capable
of becoming pregnant were excluded from the study in an abundance
of caution, due to the proven transplacental toxicity of DBC in high
dose rodent models.<sup><xref ref-type="bibr" rid="ref25">25</xref>−<xref ref-type="bibr" rid="ref31">31</xref></sup> A total of 9 volunteers were enrolled. Individual body weight, height,
BMI, age, gender, ethnicity, and race were recorded (Table <xref rid="tbl1" ref-type="other">1</xref>).</p>
                <table-wrap id="tbl1" position="float">
                  <label>Table 1</label>
                  <caption>
                    <title>Volunteer Demographics</title>
                  </caption>
                  <table frame="hsides" rules="groups" border="0">
                    <colgroup>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th style="border:none;" align="center"> </th>
                        <th style="border:none;" align="center">BW (kg)</th>
                        <th style="border:none;" align="center">Ht (cm)</th>
                        <th style="border:none;" align="center">BMI</th>
                        <th style="border:none;" align="center">age</th>
                        <th style="border:none;" align="center">gender</th>
                        <th style="border:none;" align="center">ethnicity</th>
                        <th style="border:none;" align="center">race</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td style="border:none;" align="left">V1</td>
                        <td style="border:none;" align="left">85</td>
                        <td style="border:none;" align="left">173</td>
                        <td style="border:none;" align="left">28</td>
                        <td style="border:none;" align="left">45</td>
                        <td style="border:none;" align="left">F</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Asian</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V3</td>
                        <td style="border:none;" align="left">99</td>
                        <td style="border:none;" align="left">188</td>
                        <td style="border:none;" align="left">28</td>
                        <td style="border:none;" align="left">45</td>
                        <td style="border:none;" align="left">M</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Caucasian</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V5</td>
                        <td style="border:none;" align="left">86</td>
                        <td style="border:none;" align="left">158</td>
                        <td style="border:none;" align="left">34</td>
                        <td style="border:none;" align="left">65</td>
                        <td style="border:none;" align="left">F</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Caucasian</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V6</td>
                        <td style="border:none;" align="left">94</td>
                        <td style="border:none;" align="left">196</td>
                        <td style="border:none;" align="left">24</td>
                        <td style="border:none;" align="left">47</td>
                        <td style="border:none;" align="left">M</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Caucasian</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V8</td>
                        <td style="border:none;" align="left">78</td>
                        <td style="border:none;" align="left">180</td>
                        <td style="border:none;" align="left">24</td>
                        <td style="border:none;" align="left">26</td>
                        <td style="border:none;" align="left">M</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Caucasian</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V9</td>
                        <td style="border:none;" align="left">78</td>
                        <td style="border:none;" align="left">156</td>
                        <td style="border:none;" align="left">32</td>
                        <td style="border:none;" align="left">56</td>
                        <td style="border:none;" align="left">F</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Caucasian</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V10</td>
                        <td style="border:none;" align="left">71</td>
                        <td style="border:none;" align="left">174</td>
                        <td style="border:none;" align="left">23</td>
                        <td style="border:none;" align="left">20</td>
                        <td style="border:none;" align="left">M</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Caucasian</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V11</td>
                        <td style="border:none;" align="left">113</td>
                        <td style="border:none;" align="left">180</td>
                        <td style="border:none;" align="left">35</td>
                        <td style="border:none;" align="left">43</td>
                        <td style="border:none;" align="left">M</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Caucasian</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V13</td>
                        <td style="border:none;" align="left">124</td>
                        <td style="border:none;" align="left">191</td>
                        <td style="border:none;" align="left">34</td>
                        <td style="border:none;" align="left">36</td>
                        <td style="border:none;" align="left">M</td>
                        <td style="border:none;" align="left">non-Hispanic</td>
                        <td style="border:none;" align="left">Caucasian</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
              </sec>
              <sec id="sec2.2">
                <title>Justification of the Dose
Used in This Study</title>
                <p>The 29
ng DBC dose utilized in this study is equivalent to the BaP content
of a 5.2 oz. serving of smoked meat at the European Union maximum
legal limit<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> or 28% of the average daily
dietary PAH intake.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> This chemical dose
was chosen to be relevant to typical dietary exposure in humans. The
specific activity of [l-ring-U- <sup>14</sup>C]-DBC was 51.4 nCi/nmol,
resulting in 5 nCi of [<sup>14</sup>C] in a 29 ng dose. This β
particle radiation dose of 5 nCi can be compared to the internal radiation
of consuming 5 bananas, each containing 1 nCi [<sup>40</sup>K].<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> It would require a dose of 200 study capsules
to equal the radioactive dose of a single [<sup>14</sup>C]-urea diagnostic
test for <italic>Helicobacter pylori</italic>.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> The radioactive dose was chosen to be detectable by AMS
without appreciable risk to volunteers consistent with the policy
of utilizing doses as low as Reasonably Achievable (ALARA) or Practical
(ALARP).<sup><xref ref-type="bibr" rid="ref34">34</xref></sup></p>
              </sec>
              <sec id="sec2.3">
                <title>Chemicals</title>
                <p>Dibenzo[<italic>def,p</italic>]chrysene (formerly
known as dibenzo[<italic>a,l</italic>]pyrene) [l-ring-U-<sup>14</sup>C], MRI Part No. U479C, 51.4 mCi/mmol, was obtained from the NCI
Chemical Carcinogen Standards Reference Repository, Midwest Research
Institute (Kansas City, MO). The reagents used include Ultima Flo
M scintillation cocktail, sulfuric acid, HPLC grade acetonitrile,
Milli-Q water, ethyl acetate, potassium sulfate, 95% ethanol (PCCA
50–3161), lactose monohydrate (PCCA 30-3329) and size 0 cellulose
capsules (Spectrum, Irvine CA). Chromatography utilized a Luna 3 μm
particle C<sub>18</sub> 100 Å 150 × 3 mm Phenomenex HPLC
column with a C<sub>18</sub> 2 mm guard column on an Agilent 1100
HPLC with UV detector.</p>
              </sec>
              <sec id="sec2.4">
                <title>[<sup>14</sup>C]-DBC Dosing Solution</title>
                <p>A portion of the
stock solution of [<sup>14</sup>C]-DBC (1.11 mCi/ml, 6.53 mg/mL benzene)
was blown to dryness under argon and then purified, prior to the preparation
of dosing solutions, to ≥99% radiochemical purity via reverse
phase-HPLC. HPLC elution conditions were isocratic 90% ACN, 10% H<sub>2</sub>O with a flow rate of 1 mL/min at a column temperature of
35 °C. The A<sub>280</sub> peak containing purified [<sup>14</sup>C]-DBC (6.0 to 6.5 min retention time) was collected over several
HPLC runs. The pooled eluent was evaporated to dryness under a stream
of argon and resuspended in ethanol thrice to produce the dosing solution.
An HPLC run of the dosing solution was collected in 15-s fractions
for scintillation counting to assess radioactive purity (≥99%).
The dosing solution was diluted with additional ethanol to 0.16 nCi/μL,
representing a final target dose of 29 ng DBC/30 μL dose incorporated
into each cellulose capsule. The stock solution was stored at −80
°C under argon and protected from light. All neat DBC powder
was handled by a trained carcinogen specialist in an enclosed glovebox,
per the OSU Extreme Carcinogen handling protocol. DBC solutions were
stored in a locked laboratory dedicated to carcinogens, and all waste
was discarded in accordance with OSU radiation safety and hazardous
material protocols.</p>
              </sec>
              <sec id="sec2.5">
                <title>Capsule Manufacturing and Quality Control</title>
                <p>Capsules
were prepared by filling empty cellulose capsules with pharmaceutical
grade lactose monohydrate. Thirty microliters of 0.16 nCi/μL
dosing solution was applied to the capsule and sealed by allowing
the ethanol to evaporate, inverting the capsule to create a lactose
layer above the dosing solution to prevent any possible integrity
loss upon moistening, and the capsule cap was pinched closed over
the capsule body. Every capsule batch manufactured included a dosing
capsule per volunteer plus at least 3 extra for quality control. Capsules
were stored at −20 °C until time of use and utilized within
5 days of preparation. Quality control was performed by scintillation
counting 3 randomly chosen capsules per batch, individually dissolved
by vortex in 5 mL of water prior to the addition of 15 mL of scintillation
cocktail. The variability between capsules per batch was ≤5%.
The exact dosage a volunteer received, measured by scintillation,
is included in Table <xref rid="tbl2" ref-type="other">2</xref>.</p>
                <table-wrap id="tbl2" position="float">
                  <label>Table 2</label>
                  <caption>
                    <title>Total Nanograms of [<sup>14</sup>C]-DBC<sub>eq</sub> Eliminated in
Urine during Each Collection Interval<xref rid="t2fn1" ref-type="table-fn">a</xref></title>
                  </caption>
                  <table frame="hsides" rules="groups" border="0">
                    <colgroup>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                      <col align="left"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th style="border:none;" align="center"> </th>
                        <th style="border:none;" align="center">0–6 h</th>
                        <th style="border:none;" align="center">6– 12 h</th>
                        <th style="border:none;" align="center"> 12–24 h</th>
                        <th style="border:none;" align="center">24– 48 h</th>
                        <th style="border:none;" align="center">48– 72 h</th>
                        <th style="border:none;" align="center">elim. total</th>
                        <th style="border:none;" align="center">oral dose DBC (ng)</th>
                        <th style="border:none;" align="center">% excreted</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td style="border:none;" align="left">V1</td>
                        <td style="border:none;" align="left">0.085</td>
                        <td style="border:none;" align="left">0.049</td>
                        <td style="border:none;" align="left">0.044</td>
                        <td style="border:none;" align="left">0.046</td>
                        <td style="border:none;" align="left">0.006</td>
                        <td style="border:none;" align="left">0.230</td>
                        <td style="border:none;" align="left">23.9</td>
                        <td style="border:none;" align="left">0.96</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V3</td>
                        <td style="border:none;" align="left">0.044</td>
                        <td style="border:none;" align="left">0.109</td>
                        <td style="border:none;" align="left">0.038</td>
                        <td style="border:none;" align="left">0.029</td>
                        <td style="border:none;" align="left">0.000</td>
                        <td style="border:none;" align="left">0.220</td>
                        <td style="border:none;" align="left">24.5</td>
                        <td style="border:none;" align="left">0.90</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V5</td>
                        <td style="border:none;" align="left">0.033</td>
                        <td style="border:none;" align="left">0.184</td>
                        <td style="border:none;" align="left">0.123</td>
                        <td style="border:none;" align="left">0.119</td>
                        <td style="border:none;" align="left">0.073</td>
                        <td style="border:none;" align="left">0.532</td>
                        <td style="border:none;" align="left">25.2</td>
                        <td style="border:none;" align="left">2.11</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V6</td>
                        <td style="border:none;" align="left">0.179</td>
                        <td style="border:none;" align="left">0.075</td>
                        <td style="border:none;" align="left">0.107</td>
                        <td style="border:none;" align="left">0.056</td>
                        <td style="border:none;" align="left">0.024</td>
                        <td style="border:none;" align="left">0.441</td>
                        <td style="border:none;" align="left">29.8</td>
                        <td style="border:none;" align="left">1.48</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V8</td>
                        <td style="border:none;" align="left">0.071</td>
                        <td style="border:none;" align="left">0.046</td>
                        <td style="border:none;" align="left">0.111</td>
                        <td style="border:none;" align="left">0.058</td>
                        <td style="border:none;" align="left">0.000</td>
                        <td style="border:none;" align="left">0.285</td>
                        <td style="border:none;" align="left">23.9</td>
                        <td style="border:none;" align="left">1.20</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V9</td>
                        <td style="border:none;" align="left">0.052</td>
                        <td style="border:none;" align="left">0.028</td>
                        <td style="border:none;" align="left">0.063</td>
                        <td style="border:none;" align="left">0.043</td>
                        <td style="border:none;" align="left">0.014</td>
                        <td style="border:none;" align="left">0.200</td>
                        <td style="border:none;" align="left">28.5</td>
                        <td style="border:none;" align="left">0.70</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V10</td>
                        <td style="border:none;" align="left">0.237</td>
                        <td style="border:none;" align="left">0.104</td>
                        <td style="border:none;" align="left">0.097</td>
                        <td style="border:none;" align="left">0.027</td>
                        <td style="border:none;" align="left">0.028</td>
                        <td style="border:none;" align="left">0.494</td>
                        <td style="border:none;" align="left">25.6</td>
                        <td style="border:none;" align="left">1.93</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V11</td>
                        <td style="border:none;" align="left">0.113</td>
                        <td style="border:none;" align="left">0.059</td>
                        <td style="border:none;" align="left">0.052</td>
                        <td style="border:none;" align="left">0.056</td>
                        <td style="border:none;" align="left">0.017</td>
                        <td style="border:none;" align="left">0.297</td>
                        <td style="border:none;" align="left">29.7</td>
                        <td style="border:none;" align="left">1.00</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">V13</td>
                        <td style="border:none;" align="left">0.124</td>
                        <td style="border:none;" align="left">0.056</td>
                        <td style="border:none;" align="left">0.045</td>
                        <td style="border:none;" align="left">0.033</td>
                        <td style="border:none;" align="left">0.005</td>
                        <td style="border:none;" align="left">0.263</td>
                        <td style="border:none;" align="left">28.5</td>
                        <td style="border:none;" align="left">0.92</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">average</td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left">1.24</td>
                      </tr>
                      <tr>
                        <td style="border:none;" align="left">SD</td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left"> </td>
                        <td style="border:none;" align="left">0.49</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="t2fn1">
                      <label>a</label>
                      <p>[<sup>14</sup>C]-DBC<sub>eq</sub> elimination (ng) per total urine volume in a
given pooled time point.
The percent excreted is reported as the total urine elimination divided
by the total oral dose.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec2.6">
                <title>Dosing
and Sample Collection Protocols</title>
                <p>At 8 a.m., volunteers
who had fasted overnight were orally administered a cellulose capsule
containing <sup>14</sup>C-DBC (target dose of 29 ng DBC, 5 nCi <sup>14</sup>C), which was swallowed with 100 mL of water. Food and water
were made available at 10 a.m. Blood was drawn by a registered nurse
at 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3, 4, 8, 12, 24, 48, and
72 h post-consumption and collected into glass vacutainer tubes containing
the anticoagulant, EDTA. An indwelling i.v. catheter was used for
the first 4 h of blood collection; the remaining time points were
collected by needle sticks. Initial studies using whole blood for
AMS analysis resulted in high signal-to-noise based upon background
endogenous C that obscured the <sup>14</sup>C attributable to [<sup>14</sup>C]-DBC. Therefore, whole blood was centrifuged for 10 min
at 1,000<italic>g</italic> and 0.75 mL plasma aliquots transferred
to glass culture tubes containing 0.75 g of K<sub>2</sub>SO<sub>4</sub>, to prevent emulsion, and stored at 4 °C until extracted for
AMS analysis. Urine contains low endogenous carbon, allowing AMS analysis
directly without extraction. Additional plasma and urine specimens
were stored at −80 °C for archiving.</p>
                <p>All urine voided
during the 72-h cycle was collected. Urine was pooled by 0–6,
6–12, 12–24, 24–48, and 48–72 h batches
for homogenized sampling and volume record by pool. Glass urine containers
were provided for <italic>as voided</italic> collection. Coded plasma
and plasma extracts and urine samples were stored at −20 °C
prior to shipment to Lawrence Livermore National Laboratory (LLNL)
for analysis by AMS. Archived samples were stored at −80 °C
at OSU.</p>
              </sec>
              <sec id="sec2.7">
                <title>Extraction of Plasma and Collection of Urine</title>
                <p>Plasma
samples were extracted according to the method of Crowell et al.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The samples were acidified with 0.75 mL of 0.9
M H<sub>2</sub>SO<sub>4</sub>, vortexed for 20 s, then extracted thrice
with 1 mL of ethyl acetate, and centrifugated at 750<italic>g</italic> for 10 min. The combined extracts were evaporated under argon to
dryness in an 8 mL amber glass vial with a PTFE cap liner, then stored
at −20 °C until shipped on dry ice to LLNL for AMS analysis.
As PAHs can adsorb to plastic, care was taken to use glass containers
(amber when possible) for protection from light and argon or nitrogen
capping to prevent oxidation of samples. Urine was aliquoted in 1
mL volumes for shipping, requiring no additional processing prior
to AMS preparation.</p>
              </sec>
              <sec id="sec2.8">
                <title>Extraction Efficiency</title>
                <p>The extraction
efficiency for
[<sup>14</sup>C]-DBC from plasma was determined by spiking plasma
with known amounts of [<sup>14</sup>C]-DBC using dilutions of the
[<sup>14</sup>C]-DBC microdosing ethanol stock solution. Following
ethyl acetate extraction and reconstitution with 50:50 methanol/water
(v/v) used for AMS analysis (described below), the recovery was 51
± 10% (<italic>n</italic> = 3) as determined by AMS. In a separate
test of extraction efficiency, fresh or thawed frozen plasma, 0.75
mL, was spiked with 1.25 nCi [<sup>14</sup>C]-DBC solution prior to
extraction resulting in 55 ± 7% recovery of [<sup>14</sup>C]-DBC
as detected by scintillation counting. This process was repeated with
several [<sup>14</sup>C]-DBC concentrations and with detection by
AMS and scintillation counting. Overall, across a number of concentrations,
55 ± 7% (at the low end of previously reported recoveries of
61–101% in human studies with pharaceuticals,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> perhaps due to the much lower mass of the dose utilized
in this study) was the average DBC recovery when reconstituted in
methanol/water, and this value was used for efficiency corrections
in the PK parameters reported below. Recent work by Crowell et al.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> had determined this to be the optimal extraction
method for DBC, as well as the diol, and tetraol metabolites.</p>
              </sec>
              <sec id="sec2.9">
                <title>AMS of
Plasma and Urine Samples</title>
                <p>Upon arrival at LLNL,
samples were stored at −80 °C until processing. Plasma
extract samples were reconstituted with 100 μL of 50:50 methanol/water
and converted to graphite by the method of Ognibene et al.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Urine samples (100 μL) were converted,
without prior processing, by the same graphitization method. The urine
data was not normalized for creatinine. All voided urine was collected,
pooled by time point, and volumetrically recorded prior to aliquoting
and storing pooled samples. Briefly, the samples were evaporated and
flame-sealed in a quartz tube containing Cu(II) and combusted to 900
°C, producing CO<sub>2</sub>. The CO<sub>2</sub> is then transferred
to a septa sealed glass tube containing Zn and Co and heated to 525
°C, producing graphite on the Co catalyst. The graphite is then
loaded into an aluminum sample holder for AMS analysis.</p>
                <p>AMS
analysis was conducted on the 1 MV AMS, constructed and maintained
by the Center for Accelerator Mass Spectrometry at LLNL. The current
AMS operating conditions are optimized to determine the ratio of <sup>14</sup>C/C with a precision of 3% and sensitivity of 0.4 attomol <sup>14</sup>C per mg of total carbon.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> Solid
sample standards containing <sup>14</sup>C/C content of 1.5 ×
modern are measured intermittently throughout the analysis to assess
the ionization and counting efficiency of the spectrometer. The biochemical
samples are measured 4–10 times with the collection of at least
10,000 <sup>14</sup>C counts or for 30 s each time.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup></p>
              </sec>
              <sec id="sec2.10">
                <title>Determination of Pharmacokinetic Parameters</title>
                <p>Pharmacokinetic
analysis of data utilized an Excel based add-on developed at Allergan,
Inc. (Irvine, CA).<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Briefly, the formulas
rely on noncompartmental analysis of six functions: peak concentrations
in plasma (<italic>C</italic><sub>max</sub>), time of peak plasma
concentration (<italic>T</italic><sub>max</sub>), plasma elimination
half-life (<italic>T</italic><sub>1/2</sub>), apparent elimination
rate constant (<italic>k</italic><sub>el</sub>), and area under the
plasma concentration curve (AUC<sub>0-t</sub> and AUC<sub>0-∞</sub>) using standard regression techniques.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Alpha and beta phase classifications were based on peak to trough
values. Urinary clearance (CL, mL/min) was calculated by dividing
the cumulative amount of <sup>14</sup>C eliminated in the urine over
72 h by the plasma AUC<sub>0–72h</sub>.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec3">
              <title>Results</title>
              <p>We were able to empirically determine the environmentally relevant <italic>in vivo</italic> pharmacokinetics of [<sup>14</sup>C]-DBC in human
volunteers utilizing AMS. The pool of nine volunteers included both
sexes and was characterized by an age range from 20 to 65 years of
age and BMIs from 23 to 35 (Table <xref rid="tbl1" ref-type="other">1</xref>). No recruitment
selection was made by volunteer physical characteristics. This study
was intended to assess the range of pharmacokinetics in a cross section
of human volunteers; as such, it is not statistically powered to assess
parameters such as gender, age, or BMI. Differences in age could lead
to differences in gut motility, possibly resulting in changes in absorption.
The range of BMI likely results in a range of blood volumes and distribution.
Because of a necessary change in plasma collection and processing
method, three volunteers were excluded from the plasma pharmacokinetic
analysis (Table <xref rid="tbl3" ref-type="other">3</xref> and Figure <xref rid="fig2" ref-type="fig">2</xref>); however, urine data from all nine volunteers are included
(Table <xref rid="tbl2" ref-type="other">2</xref> and Figure <xref rid="fig1" ref-type="fig">1</xref>).</p>
              <table-wrap id="tbl3" position="float">
                <label>Table 3</label>
                <caption>
                  <title>Plasma Pharmacokinetics
of DBC<sub>eq</sub> in Human Volunteers<xref rid="t3fn1" ref-type="table-fn">a</xref></title>
                </caption>
                <table frame="hsides" rules="groups" border="0">
                  <colgroup>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th style="border:none;" align="center"> </th>
                      <th style="border:none;" align="center"><italic>C</italic><sub>Max</sub> (fg·mL<sup>–1</sup>)</th>
                      <th style="border:none;" align="center"><italic>T</italic><sub>Max</sub> (h)</th>
                      <th style="border:none;" align="center">AUC-t (fg·h·mL<sup>–1</sup>)</th>
                      <th style="border:none;" align="center"><italic>K</italic><sub>el</sub> (fg·h<sup>–1</sup>)</th>
                      <th style="border:none;" align="center">AUC-<sup>∞</sup> (fg·h·mL<sup>–1</sup>)</th>
                      <th style="border:none;" align="center"><italic>T</italic><sub>1/2</sub> (h)</th>
                      <th style="border:none;" align="center">α-phase <italic>T</italic><sub>1/2</sub> (h)</th>
                      <th style="border:none;" align="center">α-phase <italic>K</italic><sub>el</sub> (fg·h<sup>–1</sup>)</th>
                      <th style="border:none;" align="center">α-phase AUC-t</th>
                      <th style="border:none;" align="center">β-elim <italic>T</italic><sub>1/2</sub> (h)</th>
                      <th style="border:none;" align="center">β-elim <italic>K</italic><sub>el</sub> (fg·h<sup>–1</sup>)</th>
                      <th style="border:none;" align="center">urinary DBC<sub>eq</sub> clearance CL(mL·min<sup>–1</sup>)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td style="border:none;" align="left">V1</td>
                      <td style="border:none;" align="left">124.1</td>
                      <td style="border:none;" align="left">1.50</td>
                      <td style="border:none;" align="left">1616</td>
                      <td style="border:none;" align="left">0.03</td>
                      <td style="border:none;" align="left">1616</td>
                      <td style="border:none;" align="left">23.5</td>
                      <td style="border:none;" align="left">6.8</td>
                      <td style="border:none;" align="left">0.10</td>
                      <td style="border:none;" align="left">462.1</td>
                      <td style="border:none;" align="left">23.6</td>
                      <td style="border:none;" align="left">0.03</td>
                      <td style="border:none;" align="left">59.4</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V6</td>
                      <td style="border:none;" align="left">118.2</td>
                      <td style="border:none;" align="left">1.50</td>
                      <td style="border:none;" align="left">2850</td>
                      <td style="border:none;" align="left">0.03</td>
                      <td style="border:none;" align="left">3690</td>
                      <td style="border:none;" align="left">27.5</td>
                      <td style="border:none;" align="left">11.7</td>
                      <td style="border:none;" align="left">0.06</td>
                      <td style="border:none;" align="left">859.1</td>
                      <td style="border:none;" align="left">66.6</td>
                      <td style="border:none;" align="left">0.01</td>
                      <td style="border:none;" align="left">15.5</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V8</td>
                      <td style="border:none;" align="left">30.4</td>
                      <td style="border:none;" align="left">1.50</td>
                      <td style="border:none;" align="left">589</td>
                      <td style="border:none;" align="left">0.03</td>
                      <td style="border:none;" align="left">699</td>
                      <td style="border:none;" align="left">23.9</td>
                      <td style="border:none;" align="left">4.8</td>
                      <td style="border:none;" align="left">0.14</td>
                      <td style="border:none;" align="left">179.7</td>
                      <td style="border:none;" align="left">28.3</td>
                      <td style="border:none;" align="left">0.02</td>
                      <td style="border:none;" align="left">48.5</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V9</td>
                      <td style="border:none;" align="left">41.6</td>
                      <td style="border:none;" align="left">4.00</td>
                      <td style="border:none;" align="left">433</td>
                      <td style="border:none;" align="left">0.05</td>
                      <td style="border:none;" align="left">604</td>
                      <td style="border:none;" align="left">13.1</td>
                      <td style="border:none;" align="left">1.7</td>
                      <td style="border:none;" align="left">0.41</td>
                      <td style="border:none;" align="left">30.7</td>
                      <td style="border:none;" align="left">10.2</td>
                      <td style="border:none;" align="left">0.07</td>
                      <td style="border:none;" align="left">46.2</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V10</td>
                      <td style="border:none;" align="left">75.0</td>
                      <td style="border:none;" align="left">2.00</td>
                      <td style="border:none;" align="left">1921</td>
                      <td style="border:none;" align="left">0.00</td>
                      <td style="border:none;" align="left">6578</td>
                      <td style="border:none;" align="left">142.2</td>
                      <td style="border:none;" align="left">5.8</td>
                      <td style="border:none;" align="left">0.12</td>
                      <td style="border:none;" align="left">236.9</td>
                      <td style="border:none;" align="left">88.6</td>
                      <td style="border:none;" align="left">0.01</td>
                      <td style="border:none;" align="left">25.7</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V13</td>
                      <td style="border:none;" align="left">23.3</td>
                      <td style="border:none;" align="left">3.00</td>
                      <td style="border:none;" align="left">237</td>
                      <td style="border:none;" align="left">0.03</td>
                      <td style="border:none;" align="left">338</td>
                      <td style="border:none;" align="left">22.1</td>
                      <td style="border:none;" align="left">3.8</td>
                      <td style="border:none;" align="left">0.18</td>
                      <td style="border:none;" align="left">74.8</td>
                      <td style="border:none;" align="left">30.6</td>
                      <td style="border:none;" align="left">0.02</td>
                      <td style="border:none;" align="left">111</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">avg</td>
                      <td style="border:none;" align="left">68.8</td>
                      <td style="border:none;" align="left">2.25</td>
                      <td style="border:none;" align="left">1274</td>
                      <td style="border:none;" align="left">0.03</td>
                      <td style="border:none;" align="left">2254</td>
                      <td style="border:none;" align="left">42.1</td>
                      <td style="border:none;" align="left">5.8</td>
                      <td style="border:none;" align="left">0.17</td>
                      <td style="border:none;" align="left">307.2</td>
                      <td style="border:none;" align="left">41.3</td>
                      <td style="border:none;" align="left">0.03</td>
                      <td style="border:none;" align="left">51.0</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">SD</td>
                      <td style="border:none;" align="left">44.3</td>
                      <td style="border:none;" align="left">1.04</td>
                      <td style="border:none;" align="left">1027</td>
                      <td style="border:none;" align="left">0.02</td>
                      <td style="border:none;" align="left">2449</td>
                      <td style="border:none;" align="left">49.3</td>
                      <td style="border:none;" align="left">3.4</td>
                      <td style="border:none;" align="left">0.12</td>
                      <td style="border:none;" align="left">309.9</td>
                      <td style="border:none;" align="left">29.8</td>
                      <td style="border:none;" align="left">0.02</td>
                      <td style="border:none;" align="left">33.4</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="t3fn1">
                    <label>a</label>
                    <p>Non compartmental analysis of pharmacokinetic
parameters.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig id="fig1" position="float">
                <label>Figure 1</label>
                <caption>
                  <p>Cumulative urinary elimination
of [<sup>14</sup>C]-DBC<sub>eq</sub> over time for six volunteers.
All voided urine was collected over
the 72 h of the study. A volumetric measurement was taken of urine
pooled by time. A sample of 1 mL of urine was measured for [<sup>14</sup>C]-DBC<sub>eq</sub> by AMS per pool, as described in <xref rid="sec2" ref-type="other">Experimental Procedures</xref>. Volumetric corrections were made
for total [<sup>14</sup>C]-DBC<sub>eq</sub> elimination per pool.
Results are recorded cumulatively.</p>
                </caption>
                <graphic xlink:href="tx-2014-003996_0002" id="gr1" position="float"/>
              </fig>
              <fig id="fig2" position="float">
                <label>Figure 2</label>
                <caption>
                  <p>[<sup>14</sup>C]-DBC<sub>eq</sub> plasma elimination curve in 6
volunteers (A) and averaged (B). (A) Plasma levels of [<sup>14</sup>C]-DBC<sub>eq</sub> over time are depicted for 6 individual volunteers
as measured by AMS as described in <xref rid="sec2" ref-type="other">Experimental Procedures</xref>. (B) This graph depicts the average and standard deviation of [<sup>14</sup>C]-DBC<sub>eq</sub> in plasma for the same 6 volunteers as
those in panel A.</p>
                </caption>
                <graphic xlink:href="tx-2014-003996_0003" id="gr2" position="float"/>
              </fig>
              <p>There were some similarities
in the temporal pattern (but not magnitude)
of absorption/excretion between individuals (Figures <xref rid="fig1" ref-type="fig">1</xref> and <xref rid="fig2" ref-type="fig">2</xref>). Levels of [<sup>14</sup>C]
in plasma rose rapidly following oral administration of [<sup>14</sup>C]-DBC to volunteers that had been fasted overnight (Tables <xref rid="tbl3" ref-type="other">3</xref> and <xref rid="tbl4" ref-type="other">4</xref>, and Figure <xref rid="fig2" ref-type="fig">2</xref>).</p>
              <table-wrap id="tbl4" position="float">
                <label>Table 4</label>
                <caption>
                  <title>Plasma DBC<sub>eq</sub> As Determined
by AMS (fg DBC<sub>eq</sub>/mL Plasma)</title>
                </caption>
                <table frame="hsides" rules="groups" border="0">
                  <colgroup>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                    <col align="left"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th style="border:none;" align="center">time (h)</th>
                      <th style="border:none;" align="center">0.00</th>
                      <th style="border:none;" align="center">0.25</th>
                      <th style="border:none;" align="center">0.50</th>
                      <th style="border:none;" align="center">0.75</th>
                      <th style="border:none;" align="center">1.0</th>
                      <th style="border:none;" align="center">1.5</th>
                      <th style="border:none;" align="center">2.0</th>
                      <th style="border:none;" align="center">2.5</th>
                      <th style="border:none;" align="center">3.0</th>
                      <th style="border:none;" align="center">4.0</th>
                      <th style="border:none;" align="center">8.0</th>
                      <th style="border:none;" align="center">12.0</th>
                      <th style="border:none;" align="center">24.0</th>
                      <th style="border:none;" align="center">48.0</th>
                      <th style="border:none;" align="center">72.0</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td style="border:none;" align="left">V1</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">13.8</td>
                      <td style="border:none;" align="left">44.1</td>
                      <td style="border:none;" align="left">88.4</td>
                      <td style="border:none;" align="left">124</td>
                      <td style="border:none;" align="left">91.7</td>
                      <td style="border:none;" align="left">61.5</td>
                      <td style="border:none;" align="left">50.1</td>
                      <td style="border:none;" align="left">45.7</td>
                      <td style="border:none;" align="left">33.8</td>
                      <td style="border:none;" align="left">33.6</td>
                      <td style="border:none;" align="left">36.5</td>
                      <td style="border:none;" align="left">18.0</td>
                      <td style="border:none;" align="left">0.0</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V6</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">27.9</td>
                      <td style="border:none;" align="left">53.7</td>
                      <td style="border:none;" align="left">87.3</td>
                      <td style="border:none;" align="left">118</td>
                      <td style="border:none;" align="left">107</td>
                      <td style="border:none;" align="left">110</td>
                      <td style="border:none;" align="left">107</td>
                      <td style="border:none;" align="left">93.4</td>
                      <td style="border:none;" align="left">69.3</td>
                      <td style="border:none;" align="left">65.1</td>
                      <td style="border:none;" align="left">34.9</td>
                      <td style="border:none;" align="left">26.5</td>
                      <td style="border:none;" align="left">21.2</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V8</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">0.4</td>
                      <td style="border:none;" align="left">6.7</td>
                      <td style="border:none;" align="left">17.4</td>
                      <td style="border:none;" align="left">25.9</td>
                      <td style="border:none;" align="left">30.4</td>
                      <td style="border:none;" align="left">25.7</td>
                      <td style="border:none;" align="left">26.9</td>
                      <td style="border:none;" align="left">25.6</td>
                      <td style="border:none;" align="left">22.1</td>
                      <td style="border:none;" align="left">14.8</td>
                      <td style="border:none;" align="left">6.1</td>
                      <td style="border:none;" align="left">10.3</td>
                      <td style="border:none;" align="left">6.2</td>
                      <td style="border:none;" align="left">3.2</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V9</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">0.4</td>
                      <td style="border:none;" align="left">15.4</td>
                      <td style="border:none;" align="left">N.D.<xref rid="t4fn1" ref-type="table-fn">a</xref></td>
                      <td style="border:none;" align="left">34.7</td>
                      <td style="border:none;" align="left">30.8</td>
                      <td style="border:none;" align="left">26.5</td>
                      <td style="border:none;" align="left">27.9</td>
                      <td style="border:none;" align="left">41.6</td>
                      <td style="border:none;" align="left">8.1</td>
                      <td style="border:none;" align="left">20.4</td>
                      <td style="border:none;" align="left">9.0</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">0.0</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V10</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">8.9</td>
                      <td style="border:none;" align="left">23.7</td>
                      <td style="border:none;" align="left">39.5</td>
                      <td style="border:none;" align="left">61.1</td>
                      <td style="border:none;" align="left">54.8</td>
                      <td style="border:none;" align="left">75.0</td>
                      <td style="border:none;" align="left">N.D.</td>
                      <td style="border:none;" align="left">37.8</td>
                      <td style="border:none;" align="left">22.6</td>
                      <td style="border:none;" align="left">17.6</td>
                      <td style="border:none;" align="left">17.3</td>
                      <td style="border:none;" align="left">33.0</td>
                      <td style="border:none;" align="left">26.1</td>
                      <td style="border:none;" align="left">22.7</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">V13</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">1.4</td>
                      <td style="border:none;" align="left">7.1</td>
                      <td style="border:none;" align="left">13.9</td>
                      <td style="border:none;" align="left">16.1</td>
                      <td style="border:none;" align="left">18.6</td>
                      <td style="border:none;" align="left">16.5</td>
                      <td style="border:none;" align="left">23.3</td>
                      <td style="border:none;" align="left">13.4</td>
                      <td style="border:none;" align="left">5.2</td>
                      <td style="border:none;" align="left">4.3</td>
                      <td style="border:none;" align="left">5.5</td>
                      <td style="border:none;" align="left">3.2</td>
                      <td style="border:none;" align="left">0.0</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">mean</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">1.5</td>
                      <td style="border:none;" align="left">12.3</td>
                      <td style="border:none;" align="left">29.5</td>
                      <td style="border:none;" align="left">55.3</td>
                      <td style="border:none;" align="left">63.1</td>
                      <td style="border:none;" align="left">58.1</td>
                      <td style="border:none;" align="left">48.2</td>
                      <td style="border:none;" align="left">45.3</td>
                      <td style="border:none;" align="left">39.8</td>
                      <td style="border:none;" align="left">24.8</td>
                      <td style="border:none;" align="left">24.5</td>
                      <td style="border:none;" align="left">21.5</td>
                      <td style="border:none;" align="left">13.3</td>
                      <td style="border:none;" align="left">7.8</td>
                    </tr>
                    <tr>
                      <td style="border:none;" align="left">SD</td>
                      <td style="border:none;" align="left">0.0</td>
                      <td style="border:none;" align="left">3.6</td>
                      <td style="border:none;" align="left">11.6</td>
                      <td style="border:none;" align="left">18.7</td>
                      <td style="border:none;" align="left">34.4</td>
                      <td style="border:none;" align="left">46.7</td>
                      <td style="border:none;" align="left">37.8</td>
                      <td style="border:none;" align="left">38.4</td>
                      <td style="border:none;" align="left">31.9</td>
                      <td style="border:none;" align="left">29.0</td>
                      <td style="border:none;" align="left">24.0</td>
                      <td style="border:none;" align="left">22.6</td>
                      <td style="border:none;" align="left">14.7</td>
                      <td style="border:none;" align="left">11.7</td>
                      <td style="border:none;" align="left">11.0</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="t4fn1">
                    <label>a</label>
                    <p>N.D., not detected.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>A <italic>T</italic><sub>max</sub> at 2.25 h was observed, followed
by a rapid α-phase elimination prior to a slower β-phase
elimination. This study was limited to the appearance and disappearance
of <sup>14</sup>C-labeled DBC<sub>eq</sub> from plasma and the levels
appearing with time in urine (a true mass balance study would have
required fecal analysis as well as determination of tissue levels
(not possible in a human study without subsequent diagnostic surgery)).
Considering differences in absorption based on motility, distribution
based on BMI, and metabolism based on polymorphisms, the pharmacokinetics
were notably consistent.</p>
              <p>Recovery of urinary <sup>14</sup>C
over 72 h yielded 1.24 ±
0.49% of the dose administered (Table <xref rid="tbl2" ref-type="other">2</xref>). Because
of the high hydrophobicity (log <italic>K</italic><sub>ow</sub> 7.4),
the majority of DBC is likely unabsorbed and eliminated in the feces
unlike 3- or 4-ring PAHs, which were reported to be rapidly absorbed
from the intestine.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> However, if we had
collected urine over a longer period and observed a pattern similar
to plasma, it could be concluded that sequestered DBC is released
slowly from the system. Oral bioavailability could be expected to
be strongly linked to the fat content of vehicle administered at dosing.<sup><xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> The fasted volunteers administered a dosing capsule with water likely
limited bioavailability. Previous high dosing studies of BaP in rodents
have resulted in minimal elimination in urine, 0.22–0.35% and
0.10–0.08% of oral dose administered, detected as known metabolites.<sup><xref ref-type="bibr" rid="ref43">43</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup> Oral gavage of mice with 15 mg/kg of DBC with corn oil vehicle yielded
4.9 to 7% urinary excretion of the total oral dose.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Administering an oral dose of 15 mg/kg DBC to mice resulted
in a <italic>T</italic><sub>max</sub> between 2 and 4 h, with detectable
DBC in blood 48 h post-gavage.</p>
            </sec>
            <sec sec-type="discussion" id="sec4">
              <title>Discussion</title>
              <p>As environmental PAHs
occur in complex mixtures, ingestion/elimination
kinetics in humans from PAH exposures are difficult to discern. The
translation of high dose animal experiment data for human risk assessment
is often criticized as being of questionable relevance for human exposures.
Because of the sensitivity of AMS, we are able to assess the <italic>in vivo</italic> human metabolic parameters of one of the most carcinogenic
PAHs in animal models, DBC, while maintaining risk to volunteers at
a <italic>de minimus</italic> level. Our pharmacokinetic data set
following human DBC exposure at environmentally relevant levels offer
an excellent biomonitoring tool for agencies charged with risk assessment
and modeling to humans of high molecular weight carcinogenic PAHs.</p>
              <p>PAHs are pro-carcinogens, requiring enzymatic activation to electrophilic
metabolites such as epoxides, dihydrodiol-epoxides, and quinones.<sup><xref ref-type="bibr" rid="ref45">45</xref>,<xref ref-type="bibr" rid="ref46">46</xref></sup> These electrophiles have numerous nucleophilic targets in the cell
including DNA. In the case of DBC, cytochrome P450 (P450)-dependent
11,12-epoxygenation followed by hydrolysis (epoxide hydrolase) and
a second epoxygenation produces the 11,12-dihydrodiol-13,14-epoxide
(DBCDE). Of the four possible enantiomers, the (−)-<italic>anti</italic>-11<italic>R</italic>,12<italic>S</italic>-dihydrodiol-13<italic>S</italic>,14<italic>R</italic>-epoxide or (−)-<italic>anti</italic>-DBCDE is thought to be the most efficient at forming DNA adducts
at a number of sites on purine bases<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> especially
at N<sup>6</sup>-dA and N<sup>2</sup>-dG. Understanding the extent
of metabolism, both bioactivation and detoxication (conjugation by
SULTs, UGTs, and GSTs), following exposure to environmentally relevant
doses would greatly add to the impact of Bio-AMS studies such as this
one. The same is true for the determination of the extent and identity
of DNA adducts in peripheral blood mononucleocytes following microdosing.</p>
              <p>A current strength and drawback to the solid sample Bio-AMS technology
employed in this study is that only total [<sup>14</sup>C] label is
detected. While providing sensitivity in the attomole range, this
method is not capable of speciation, i.e., chemical identification
and quantification of the parent compound and metabolites. Previously,
to identify metabolites, plasma extracts would have to be separated
by HPLC and collected as discrete fractions, based on the retention
time of metabolite standards, prior to graphitization.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> This approach is burdened with the same limitations
of HPLC fraction collection for uncoupled traditional MS. HPLC fraction
selection is based on the retention time of commercially available
standards for downstream MS analysis. Only select fractions can be
analyzed due to study limitations, including manual sample preparation.</p>
              <p>New instrumentation at LLNL provides liquid sample AMS through
the interface of UHPLC and AMS and determination of the metabolite
profile.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> Moving wire coupled UHPLC-Bio-AMS
(liquid sample Bio-AMS) technology combusts column eluent to <sup>14</sup>CO<sub>2,</sub> prior to AMS carbon isotope detection across
an entire chromatographic run. Parent, metabolite, and all conjugated
species present from a biological matrix such as plasma, urine, or
isolated DNA adducts can be detected and quantitated. Standards are
necessary for identification based on retention time, but all species
resulting from metabolism would be represented in the <sup>14</sup>C tracing. Future work will focus on utilizing liquid sample Bio-AMS
to identify the species and concentration of PAH metabolites over
time and examination of interindividual differences such as genetics
or previously environmental exposures, elucidating gene-environmental
interactions at microdoses. One such study is currently underway in
our laboratory. A targeted total of 75 enrollees will be dosed with
5 nCi (46 ng) of [<sup>14</sup>C]-BaP. Plasma and urine levels of
parent [<sup>14</sup>C]-BaP and [<sup>14</sup>C]-BaP metabolites will
be assessed over a 72 h period employing UHPLC-AMS<sup>14</sup> (FDA
IND #117175; OSU IRB #5644). Preliminary results to date (Figure <xref rid="fig3" ref-type="fig">3</xref>) show that the majority of the <sup>14</sup>C counts
in plasma coelute with DBC with minor amounts of [<sup>14</sup>C]-DBC-11,12-dihydrodiol
tentatively identified by coelution with unlabeled standard (synthesized
and provided by Dr. Shantu Amin, Penn State University). The apparent
peak eluting early (2–2.5 min) is unknown. It should be noted
that this is the first sample run by UHLPC and is from plasma (not
urine, where metabolites should predominant). Extraction at later
time points (or pooling of some time points) and from higher volumes
of plasma should allow us to better quantify these putative metabolites.</p>
              <fig id="fig3" position="float">
                <label>Figure 3</label>
                <caption>
                  <p>UHPLC-AMS
of [<sup>14</sup>C]-DBC and putative metabolites from
plasma of volunteer 5 3 h following dosing. Plasma samples were extracted
twice with 50 μL of ethyl acetate and the extract transferred
to an HPLC vial with a 300 μL insert. The ethyl acetate was
evaporated in a vacuum chamber and the residue reconstituted with
50 μL of acetonitrile prior to injection. Five microliters of
plasma extract (volunteer 5, 3 h after dosing) was injected onto a
Phenomenex Kinetex 2.6 μm C<sub>18</sub> 100 Å (Part no:
00f-4462-AN) column (150 × 2.1 mm) fitted with a C<sub>18</sub> guard column and eluted with 45% acetonitrile for 0–3 min
followed by a linear gradient (3–10 min) to 100% acetonitrile,
which was maintained from 10 to 13 min before a return to initial
conditions (flow rate of 0.12 mL·min<sup>–1</sup> (25
°C)). Following passage through a dual channel UV/vis detector
(280 and 315 nm), the eluent was deposited onto a moving nickel wire
and the [<sup>14</sup>C]-DBC<sub>eq</sub> converted to <sup>14</sup>CO<sub>2</sub> prior to AMS analysis.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> Multiple channels allow for the simultaneous determination of A<sub>280</sub> and A<sub>315</sub> as well as counts of <sup>12</sup>C
and <sup>14</sup>C. Only the <sup>14</sup>C profile is shown here.
The use of unlabeled parent DBC and standards (DBC-(±)-11,12-diol
and DBC-(±)-11,12,13,14-tetraol) allow for tentative identification
of <sup>14</sup>C peaks (top panel). The polar putative metabolite
eluting between 2 and 2.5 min is currently unknown but could be a
conjugate formed by sulfotransferases or UDP-glucuronosyl transferase
(sample not treated with sulfatase or β-glucuronidase prior
to analysis). The plasma sample from volunteer 5 (lower panel) shows
a detectable peak at 13.5 min, which is the retention time (top panel)
of DBC-(±)-diol. The major <sup>14</sup>C-containing peak in
plasma at 3 h postdosing coelutes with parent DBC.</p>
                </caption>
                <graphic xlink:href="tx-2014-003996_0004" id="gr3" position="float"/>
              </fig>
              <p>We used a previously published PBPK model developed
for the rat<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> to evaluate how well the
human [<sup>14</sup>C]-DBC<sub>eq</sub> pharmacokinetic profile compared
with that of
other species. For this comparison (Figure <xref rid="fig4" ref-type="fig">4</xref>), we scaled the initial step in the human metabolism of DBC from
rate constants determined from rats. Otherwise, the human PBPK model
was based upon average anatomy and physiology of a 70 kg adult male
under the dosing conditions used in this study. When human metabolism
was scaled from the rat, the PBPK simulation of parent DBC pharmacokinetics
in plasma was remarkably close to the measured data during the first
12 h postdosing. At later time points, the model simulations of DBC
kinetics began to significantly under predict the total <sup>14</sup>C data, which likely represented an increasing proportion of DBC
metabolites. As described above, studies are ongoing to quantitate
DBC and its major metabolites in plasma and urine samples from this
study to more directly compare with PBPK predictions. These data,
along with recently published data on species differences in metabolic
rate constants associated with DBC metabolism,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> will be incorporated into the next generation PBPK model
to improve cross-species comparisons. Nevertheless, these initial
comparisons based upon simple metabolic scaling assumptions are encouraging.</p>
              <fig id="fig4" position="float">
                <label>Figure 4</label>
                <caption>
                  <p>Pharmacokinetic
profile of [<sup>14</sup>C]-DBC<sub>eq</sub> in
humans: comparison to a rat PBPK model. The ● symbols are plasma
levels over time of [<sup>14</sup>C]-DBC<sub>eq</sub> (with error
bars depicting ± SD) following microdosing of humans with 5 nCi
(29 ng) of [<sup>14</sup>C]-DBC. The solid curve is PBPK model prediction
with metabolic rate scaled from the rat as calculated by Crowell et
al.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup></p>
                </caption>
                <graphic xlink:href="tx-2014-003996_0005" id="gr4" position="float"/>
              </fig>
              <p>The pharmacokinetics of phenanthrene (a 3-ring PAH) and its
diol
and tetraol metabolites have been conducted in humans following oral
or inhalation exposure to 10 μg of [D<sub>10</sub>]-phenanthrene
and analysis of plasma and urine over time by GC-electron impact-MS/MS.<sup><xref ref-type="bibr" rid="ref49">49</xref>−<xref ref-type="bibr" rid="ref51">51</xref></sup> Phenanthrene can act as a surrogate for larger molecular weight
carcinogenic PAHs<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> as it has a bay region
and is metabolized in a manner similar to that of BaP but is designated
a class C PAH by IARC<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and has been given
an RPF of 0 by EPA.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> In our subsequent
studies characterizing the pharmacokinetics of BaP and its metabolites
by UHPLC-AMS following microdosing with 46 ng, we hope to examine
the impact of genetic polymorphisms in BaP-metabolizing enzymes as
was done by Wang et al.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> Likewise, we
plan to examine [<sup>14</sup>C]-PAH-derived DNA and protein adducts
from peripheral blood mononuclear cells (PBMCs) as potential biomarkers
of exposure and perhaps risk following microdosing. The use of moving
wire technology may provide the opportunity to identify macromolecular
adduct profiles.</p>
              <p>The ability to determine the pharmacokinetic
parameters, safely
in humans, of carcinogenic chemicals found in the environment and
their metabolites is an advancement in risk assessment. Further development
and application of this technology could have a major impact in the
arena of human environmental health.</p>
            </sec>
          </body>
          <back>
            <notes id="notes-1" notes-type="funding-statement">
              <p>This study was
funded by PHS grants P42ES016465, K.C. Donnelly Supplement P42ES016465,
P41GM103483, and T32ES07060. AMS was performed at the Research Resource
for Biomedical AMS, which is operated at LLNL under the auspices of
the U.S. Department of Energy under contract DE-AC52-07NA27344 and
National Institute of General Medical Sciences 8P41 GM103483-14.</p>
            </notes>
            <notes id="NOTES-d2083e2260-autogenerated" notes-type="conflict-of-interest">
              <p>The authors declare
no
competing financial interest.</p>
            </notes>
            <ack>
              <title>Acknowledgments</title>
              <p>We acknowledge the pharmaceutical expertise and contribution
of materials provided by Dr. Mark Christensen (College of Pharmacy,
Oregon State University).</p>
            </ack>
            <glossary id="dl1">
              <def-list>
                <title>Abbreviations</title>
                <def-item>
                  <term>ACN</term>
                  <def>
                    <p>acetonitrile</p>
                  </def>
                </def-item>
                <def-item>
                  <term>AMS</term>
                  <def>
                    <p>accelerator mass spectrometry</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ATSDR</term>
                  <def>
                    <p>Agency for Toxic
Substances and Disease Registry</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BaP</term>
                  <def>
                    <p>benzo[<italic>a</italic>]pyrene</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BMI</term>
                  <def>
                    <p>body mass index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DBC</term>
                  <def>
                    <p>dibenzo[<italic>def,p</italic>]chrysene</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DBCDE</term>
                  <def>
                    <p>dibenzo[<italic>def,p</italic>]chrysene-11,12-dihydrodiol-13,14-epoxide</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DBC<sub>eq</sub></term>
                  <def>
                    <p>dibenzo[<italic>def,p</italic>]chrysene equivalents (DBC plus metabolites)</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DDT</term>
                  <def>
                    <p>1,1,1-trichloro-2,2-di(4-chlorophenyl)ethane</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GSTs</term>
                  <def>
                    <p>glutathione-<italic>S</italic>-transferases</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HPLC</term>
                  <def>
                    <p>high pressure liquid chromatography</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IARC</term>
                  <def>
                    <p>International Agency for Research
on Cancer</p>
                  </def>
                </def-item>
                <def-item>
                  <term>JECFA</term>
                  <def>
                    <p>Joint FAO/WHO Expert Committee on Food Additives</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LLNL</term>
                  <def>
                    <p>Lawrence Livermore National Laboratory</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MeIQ</term>
                  <def>
                    <p>2-amino-3,4-dimethylimidazo[4,5-<italic>f</italic>]quinoline</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MeIQx</term>
                  <def>
                    <p>2-amino-3,8-dimethylimidazo[4,5-<italic>f</italic>]quinoxaline</p>
                  </def>
                </def-item>
                <def-item>
                  <term>OSU</term>
                  <def>
                    <p>Oregon State University</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PAH</term>
                  <def>
                    <p>polycyclic aromatic
hydrocarbon</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PBPK</term>
                  <def>
                    <p>physiologically based pharmacokinetic model</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PhIP</term>
                  <def>
                    <p>2-amino-1-methyl-6-phenylimidazo[4,5-<italic>b</italic>]pyridine</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PCBs</term>
                  <def>
                    <p>polychlorinated biphenyls</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SD</term>
                  <def>
                    <p>standard deviation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SULTs</term>
                  <def>
                    <p>sulfotransferases</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TCDD</term>
                  <def>
                    <p>2,3,7,8-tetrachlorodibenzo-<italic>p</italic>-dioxin</p>
                  </def>
                </def-item>
                <def-item>
                  <term>UGTs</term>
                  <def>
                    <p>UDP-glucuronosyltransferases</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ref-list>
              <title>References</title>
              <ref id="ref1">
                <mixed-citation publication-type="book" id="cit1"><collab>IARC</collab> (<year>2010</year>) <source>Monographs on the Evaluation of Carcinogenic
Risks to Humans, Some Non-Heterocyclic Polycyclic Aromatic Hydrocarbons
and Some Exposures</source>, <publisher-name>World Health Organization
International Agency for Research on Cancer</publisher-name>, <publisher-loc>Lyon, France</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="ref2">
                <mixed-citation publication-type="report" id="cit2"><collab>ATSDR</collab> (<year>2013</year>) <source>Priority List of Hazardous
Substances</source>, Agency for Toxic Substances and Disease Registry,
Center for Disease Control, <uri xlink:href="http://www.atsdr.cdc.gov/spl/resources/ATSDR_2013_SPL_Detailed_Data_Table.pdf">http://www.atsdr.cdc.gov/spl/resources/ATSDR_2013_SPL_Detailed_Data_Table.pdf</uri>.</mixed-citation>
              </ref>
              <ref id="ref3">
                <mixed-citation publication-type="book" id="cit3"><collab>IARC</collab> (<year>1983</year>) <source>Monographs
on the Evaluation of Carcinogenic
Risks to Humans, Polynuclear Aromatic Compounds, Part 1: Chemical,
Environmental, and Experimental Data</source>, <publisher-name>World
Health Organization International Agency for Research on Cancer</publisher-name>, <publisher-loc>Lyon, France</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="ref4">
                <mixed-citation publication-type="journal" id="cit4"><name><surname>Dennis</surname><given-names>M. J.</given-names></name>; <name><surname>Massey</surname><given-names>R. C.</given-names></name>; <name><surname>Cripps</surname><given-names>G.</given-names></name>; <name><surname>Venn</surname><given-names>I.</given-names></name>; <name><surname>Howarth</surname><given-names>N.</given-names></name>; <name><surname>Lee</surname><given-names>G.</given-names></name> (<year>1991</year>) <article-title>Factors affecting the polycyclic aromatic hydrocarbon content of
cereals, fats and other food-products</article-title>. <source>Food
Addit. Contam.</source>
<volume>8</volume>, <fpage>517</fpage>–<lpage>530</lpage>.<pub-id pub-id-type="pmid">1806403</pub-id></mixed-citation>
              </ref>
              <ref id="ref5">
                <mixed-citation publication-type="journal" id="cit5"><name><surname>Jakszyn</surname><given-names>P.</given-names></name>; <name><surname>Agudo</surname><given-names>A.</given-names></name>; <name><surname>Ibanez</surname><given-names>R.</given-names></name>; <name><surname>Garcia-Closas</surname><given-names>R.</given-names></name>; <name><surname>Pera</surname><given-names>G.</given-names></name>; <name><surname>Amiano</surname><given-names>P.</given-names></name>; <name><surname>Gonzalez</surname><given-names>C. A.</given-names></name> (<year>2004</year>) <article-title>Development
of a
food database of nitrosamines, heterocyclic amines, and polycyclic
aromatic hydrocarbons</article-title>. <source>J. Nutr.</source>
<volume>134</volume>, <fpage>2011</fpage>–<lpage>2014</lpage>.<pub-id pub-id-type="pmid">15284391</pub-id></mixed-citation>
              </ref>
              <ref id="ref6">
                <mixed-citation publication-type="journal" id="cit6"><name><surname>Santodonato</surname><given-names>J.</given-names></name>; <name><surname>Howard</surname><given-names>P.</given-names></name>; <name><surname>Basu</surname><given-names>D.</given-names></name> (<year>1981</year>) <article-title>Health and
ecological assessment
of polynuclear aromatic hydrocarbons</article-title>. <source>J. Environ.
Pathol. Toxicol.</source>
<volume>5</volume>, <fpage>1</fpage>–<lpage>364</lpage>.<pub-id pub-id-type="pmid">7310260</pub-id></mixed-citation>
              </ref>
              <ref id="ref7">
                <mixed-citation publication-type="journal" id="cit7"><name><surname>Hattemerfrey</surname><given-names>H. A.</given-names></name>; <name><surname>Travis</surname><given-names>C. C.</given-names></name> (<year>1991</year>) <article-title>Benzo(a)pyrene environmental partitioning and human
exposure</article-title>. <source>Toxicol. Indust. Health</source>
<volume>7</volume>, <fpage>141</fpage>–<lpage>157</lpage>.</mixed-citation>
              </ref>
              <ref id="ref8">
                <mixed-citation publication-type="journal" id="cit8"><name><surname>Kazerouni</surname><given-names>N.</given-names></name>; <name><surname>Sinha</surname><given-names>R.</given-names></name>; <name><surname>Hsu</surname><given-names>C. H.</given-names></name>; <name><surname>Greenberg</surname><given-names>A.</given-names></name>; <name><surname>Rothman</surname><given-names>N.</given-names></name> (<year>2001</year>) <article-title>Analysis of 200 food items for benzo[<italic>a</italic>]pyrene and estimation of its intake in an epidemiologic
study</article-title>. <source>Food Chem. Toxicol.</source>
<volume>39</volume>, <fpage>423</fpage>–<lpage>436</lpage>.<pub-id pub-id-type="pmid">11313108</pub-id></mixed-citation>
              </ref>
              <ref id="ref9">
                <mixed-citation publication-type="book" id="cit9"><collab>JECFA</collab> (<year>2005</year>) <source>Sixty-fourth International
Meeting Abstracts</source>, <publisher-name>Joint Food and Agriculture
Organization/World Health
Organization Expert Committee on Food Additives</publisher-name>, <publisher-loc>Rome, Italy</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="ref10">
                <mixed-citation publication-type="journal" id="cit10"><name><surname>Menzie</surname><given-names>C. A.</given-names></name>; <name><surname>Potocki</surname><given-names>B. B.</given-names></name>; <name><surname>Santodonato</surname><given-names>J.</given-names></name> (<year>1992</year>) <article-title>Exposure to carcinogenic PAHs in
the environment</article-title>. <source>Environ. Sci. Technol.</source>
<volume>26</volume>, <fpage>1278</fpage>–<lpage>1284</lpage>.</mixed-citation>
              </ref>
              <ref id="ref11">
                <mixed-citation publication-type="journal" id="cit11"><name><surname>Veyrand</surname><given-names>B.</given-names></name>; <name><surname>Sirot</surname><given-names>V.</given-names></name>; <name><surname>Durand</surname><given-names>S.</given-names></name>; <name><surname>Pollono</surname><given-names>C.</given-names></name>; <name><surname>Matchand</surname><given-names>P.</given-names></name>; <name><surname>Dervilly-Pinel</surname><given-names>G.</given-names></name>; <name><surname>Tard</surname><given-names>A.</given-names></name>; <name><surname>Leblanc</surname><given-names>J. C.</given-names></name>; <name><surname>Le Bizec</surname><given-names>B.</given-names></name> (<year>2013</year>) <article-title>Human dietary
exposure to polycyclic aromatic hydrocarbons: Results of the second
French total diet study</article-title>. <source>Environ. Int.</source>
<volume>54</volume>, <fpage>11</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">23376598</pub-id></mixed-citation>
              </ref>
              <ref id="ref12">
                <mixed-citation publication-type="journal" id="cit12"><name><surname>Crowell</surname><given-names>S. R.</given-names></name>; <name><surname>Amin</surname><given-names>S. G.</given-names></name>; <name><surname>Anderson</surname><given-names>K. A.</given-names></name>; <name><surname>Krishnegowda</surname><given-names>G.</given-names></name>; <name><surname>Sharma</surname><given-names>A. K.</given-names></name>; <name><surname>Soelberg</surname><given-names>J. J.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name>; <name><surname>Corley</surname><given-names>R. A.</given-names></name> (<year>2011</year>) <article-title>Preliminary
physiologically based pharmacokinetic models for benzo[a]pyrene and
dibenzo[<italic>def,p</italic>]chrysene in rodents</article-title>. <source>Toxicol. Appl. Pharmacol.</source>
<volume>257</volume>, <fpage>365</fpage>–<lpage>376</lpage>.<pub-id pub-id-type="pmid">22001385</pub-id></mixed-citation>
              </ref>
              <ref id="ref13">
                <mixed-citation publication-type="journal" id="cit13"><name><surname>Crowell</surname><given-names>S. R.</given-names></name>; <name><surname>Sharma</surname><given-names>A. K.</given-names></name>; <name><surname>Amin</surname><given-names>S.</given-names></name>; <name><surname>Soelberg</surname><given-names>J. J.</given-names></name>; <name><surname>Sadler</surname><given-names>N. C.</given-names></name>; <name><surname>Wright</surname><given-names>A. T.</given-names></name>; <name><surname>Baird</surname><given-names>W. M.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name>; <name><surname>Corley</surname><given-names>R. A.</given-names></name> (<year>2013</year>) <article-title>Impact
of pregnancy on the pharmacokinetics of dibenzo[<italic>def,p</italic>]chrysene in mice</article-title>. <source>Toxicol. Sci.</source>
<volume>135</volume>, <fpage>48</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">23744095</pub-id></mixed-citation>
              </ref>
              <ref id="ref14">
                <mixed-citation publication-type="journal" id="cit14"><name><surname>Brown</surname><given-names>K.</given-names></name>; <name><surname>Tompkins</surname><given-names>E. M.</given-names></name>; <name><surname>White</surname><given-names>I. N. H.</given-names></name> (<year>2006</year>) <article-title>Applications
of accelerator mass
spectrometry for pharmacological and toxicological research</article-title>. <source>Mass Spectrom. Rev.</source>
<volume>25</volume>, <fpage>127</fpage>–<lpage>145</lpage>.<pub-id pub-id-type="pmid">16059873</pub-id></mixed-citation>
              </ref>
              <ref id="ref15">
                <mixed-citation publication-type="journal" id="cit15"><name><surname>Forsgard</surname><given-names>N.</given-names></name>; <name><surname>Salehpour</surname><given-names>M.</given-names></name>; <name><surname>Possnert</surname><given-names>G.</given-names></name> (<year>2010</year>) <article-title>Accelerator mass spectrometry in
the attomolar concentration range for <sup>14</sup>C-labeled biologically
active compounds in complex matrixes</article-title>. <source>J. Anal.
At. Spectrom.</source>
<volume>25</volume>, <fpage>74</fpage>–<lpage>78</lpage>.</mixed-citation>
              </ref>
              <ref id="ref16">
                <mixed-citation publication-type="journal" id="cit16"><name><surname>Dueker</surname><given-names>S.
R.</given-names></name>; <name><surname>Lohstroh</surname><given-names>P. N.</given-names></name>; <name><surname>Giacomo</surname><given-names>J. A.</given-names></name>; <name><surname>Le</surname><given-names>T. V.</given-names></name>; <name><surname>Keck</surname><given-names>B. D.</given-names></name>; <name><surname>Vogel</surname><given-names>J. S.</given-names></name> (<year>2010</year>) <article-title>Early human
ADME using microdoses and microtracers:
bioanalytical considerations</article-title>. <source>Bioanaly</source>
<volume>2</volume>, <fpage>441</fpage>–<lpage>454</lpage>.</mixed-citation>
              </ref>
              <ref id="ref17">
                <mixed-citation publication-type="journal" id="cit17"><name><surname>Dueker</surname><given-names>S. R.</given-names></name>; <name><surname>Vuong</surname><given-names>L. T.</given-names></name>; <name><surname>Lohstroh</surname><given-names>P. N.</given-names></name>; <name><surname>Giacomo</surname><given-names>J. A.</given-names></name>; <name><surname>Voegel</surname><given-names>J. S.</given-names></name> (<year>2011</year>) <article-title>Quantifying
exploratory low dose compounds in humans with AMS</article-title>. <source>Adv. Drug Delivery Rev.</source>
<volume>63</volume>, <fpage>518</fpage>–<lpage>531</lpage>.</mixed-citation>
              </ref>
              <ref id="ref18">
                <mixed-citation publication-type="journal" id="cit18"><name><surname>Penner</surname><given-names>N.</given-names></name>; <name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Prakash</surname><given-names>C.</given-names></name> (<year>2012</year>) <article-title>Radiolabeled absorption, distribution, metabolism,
and excretion studies in drug development: why, when, and how?</article-title>. <source>Chem. Res. Toxicol.</source>
<volume>25</volume>, <fpage>513</fpage>–<lpage>531</lpage>.<pub-id pub-id-type="pmid">22309195</pub-id></mixed-citation>
              </ref>
              <ref id="ref19">
                <mixed-citation publication-type="journal" id="cit19"><name><surname>Dingley</surname><given-names>K. H.</given-names></name>; <name><surname>Curtis</surname><given-names>K. D.</given-names></name>; <name><surname>Nowell</surname><given-names>S.</given-names></name>; <name><surname>Felton</surname><given-names>J. S.</given-names></name>; <name><surname>Lang</surname><given-names>N. P.</given-names></name>; <name><surname>Turteltaub</surname><given-names>K. W.</given-names></name> (<year>1999</year>) <article-title>DNA and protein adduct formation in the colon and blood
of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo
[4,5-<italic>b</italic>] pyridine</article-title>. <source>Cancer Epidemiol.
Biomarkers Prev.</source>
<volume>8</volume>, <fpage>507</fpage>–<lpage>512</lpage>.<pub-id pub-id-type="pmid">10385140</pub-id></mixed-citation>
              </ref>
              <ref id="ref20">
                <mixed-citation publication-type="journal" id="cit20"><name><surname>Dingley</surname><given-names>K. H.</given-names></name>; <name><surname>Freeman</surname><given-names>S.</given-names></name>; <name><surname>Nelson</surname><given-names>D. O.</given-names></name>; <name><surname>Garner</surname><given-names>R. C.</given-names></name>; <name><surname>Turteltaub</surname><given-names>K. W.</given-names></name> (<year>1998</year>) <article-title>Covalent
binding of 2-amino-3,8-dimethylimidazo [4,5-<italic>f</italic>] quinoxaline
to albumin and hemoglobin at environmentally relevant doses - Comparison
of human subjects and F344 rats</article-title>. <source>Drug Metab.
Dispos.</source>
<volume>26</volume>, <fpage>825</fpage>–<lpage>828</lpage>.<pub-id pub-id-type="pmid">9698300</pub-id></mixed-citation>
              </ref>
              <ref id="ref21">
                <mixed-citation publication-type="journal" id="cit21"><name><surname>Garner</surname><given-names>R.
C.</given-names></name>; <name><surname>Lightfoot</surname><given-names>T. J.</given-names></name>; <name><surname>Cupid</surname><given-names>B. C.</given-names></name>; <name><surname>Russell</surname><given-names>D.</given-names></name>; <name><surname>Coxhead</surname><given-names>J. M.</given-names></name>; <name><surname>Kutschera</surname><given-names>W.</given-names></name>; <name><surname>Priller</surname><given-names>A.</given-names></name>; <name><surname>Rom</surname><given-names>W.</given-names></name>; <name><surname>Steier</surname><given-names>P.</given-names></name>; <name><surname>Alexander</surname><given-names>D. J.</given-names></name>; <name><surname>Leveson</surname><given-names>S. H.</given-names></name>; <name><surname>Dingley</surname><given-names>K. H.</given-names></name>; <name><surname>Mauthe</surname><given-names>R. J.</given-names></name>; <name><surname>Turteltaub</surname><given-names>K. W.</given-names></name> (<year>1999</year>) <article-title>Comparative
biotransformation studies of MeIQx and
PhIP in animal models and humans</article-title>. <source>Cancer Lett.</source>
<volume>143</volume>, <fpage>161</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">10503897</pub-id></mixed-citation>
              </ref>
              <ref id="ref22">
                <mixed-citation publication-type="journal" id="cit22"><name><surname>Lang</surname><given-names>N. P.</given-names></name>; <name><surname>Nowell</surname><given-names>S.</given-names></name>; <name><surname>Malfatti</surname><given-names>M. A.</given-names></name>; <name><surname>Kulp</surname><given-names>K. S.</given-names></name>; <name><surname>Knize</surname><given-names>M. G.</given-names></name>; <name><surname>Davis</surname><given-names>C.</given-names></name>; <name><surname>Massengill</surname><given-names>J.</given-names></name>; <name><surname>Williams</surname><given-names>S.</given-names></name>; <name><surname>MacLeod</surname><given-names>S.</given-names></name>; <name><surname>Dingley</surname><given-names>K. H.</given-names></name>; <name><surname>Felton</surname><given-names>J. S.</given-names></name>; <name><surname>Turteltaub</surname><given-names>K. W.</given-names></name> (<year>1999</year>) <article-title><italic>In vivo</italic> human metabolism of [2-<sup>14</sup>C]2-amino-1-methyl-6-phenylimidazo-[4,5-<italic>b</italic>] pyridine (PhIP)</article-title>. <source>Cancer Lett.</source>
<volume>143</volume>, <fpage>135</fpage>–<lpage>138</lpage>.<pub-id pub-id-type="pmid">10503892</pub-id></mixed-citation>
              </ref>
              <ref id="ref23">
                <mixed-citation publication-type="journal" id="cit23"><name><surname>Lightfoot</surname><given-names>T. J.</given-names></name>; <name><surname>Coxhead</surname><given-names>J. M.</given-names></name>; <name><surname>Cupid</surname><given-names>B. C.</given-names></name>; <name><surname>Nicholson</surname><given-names>S.</given-names></name>; <name><surname>Garner</surname><given-names>R. C.</given-names></name> (<year>2000</year>) <article-title>Analysis of DNA adducts by accelerator
mass spectrometry
in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo
[4,5-<italic>b</italic>] pyridine and benzo[<italic>a</italic>]pyrene</article-title>. <source>Mutat. Res., Genet. Toxicol. Environ. Mutagen.</source>
<volume>472</volume>, <fpage>119</fpage>–<lpage>127</lpage>.</mixed-citation>
              </ref>
              <ref id="ref24">
                <mixed-citation publication-type="journal" id="cit24"><name><surname>Jubert</surname><given-names>C.</given-names></name>; <name><surname>Mata</surname><given-names>J.</given-names></name>; <name><surname>Bench</surname><given-names>G.</given-names></name>; <name><surname>Dashwood</surname><given-names>R.</given-names></name>; <name><surname>Pereira</surname><given-names>C.</given-names></name>; <name><surname>Tracewell</surname><given-names>W.</given-names></name>; <name><surname>Turteltaub</surname><given-names>K.</given-names></name>; <name><surname>Williams</surname><given-names>D.</given-names></name>; <name><surname>Bailey</surname><given-names>G.</given-names></name> (<year>2009</year>) <article-title>Effects of
chlorophyll and chlorophyllin on low-dose aflatoxin B<sub>1</sub> pharmacokinetics
in human volunteers</article-title>. <source>Cancer Prev. Res.</source>
<volume>2</volume>, <fpage>1015</fpage>–<lpage>1022</lpage>.</mixed-citation>
              </ref>
              <ref id="ref25">
                <mixed-citation publication-type="journal" id="cit25"><name><surname>Castro</surname><given-names>D. J.</given-names></name>; <name><surname>Baird</surname><given-names>W. M.</given-names></name>; <name><surname>Pereira</surname><given-names>C. B.</given-names></name>; <name><surname>Giovanini</surname><given-names>J.</given-names></name>; <name><surname>Löhr</surname><given-names>C. V.</given-names></name>; <name><surname>Fischer</surname><given-names>K. A.</given-names></name>; <name><surname>Yu</surname><given-names>Z.</given-names></name>; <name><surname>Gonzalez</surname><given-names>F. J.</given-names></name>; <name><surname>Krueger</surname><given-names>S. K.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name> (<year>2008</year>) <article-title>Fetal mouse Cyp1b1
and transplacental
carcinogenesis from maternal exposure to dibenzo(<italic>a,l</italic>)pyrene</article-title>. <source>Cancer Prev. Res.</source>
<volume>1</volume>, <fpage>128</fpage>–<lpage>134</lpage>.</mixed-citation>
              </ref>
              <ref id="ref26">
                <mixed-citation publication-type="journal" id="cit26"><name><surname>Castro</surname><given-names>D. J.</given-names></name>; <name><surname>Löhr</surname><given-names>C. V.</given-names></name>; <name><surname>Fischer</surname><given-names>K. A.</given-names></name>; <name><surname>Pereira</surname><given-names>C. B.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name> (<year>2008</year>) <article-title>Lymphoma
and lung cancer in offspring born to pregnant mice dosed with dibenzo[<italic>a,l</italic>]pyrene: The importance of <italic>in utero</italic> vs.
lactational exposure</article-title>. <source>Toxicol. Appl. Pharmacol.</source>
<volume>233</volume>, <fpage>454</fpage>–<lpage>458</lpage>.<pub-id pub-id-type="pmid">18848954</pub-id></mixed-citation>
              </ref>
              <ref id="ref27">
                <mixed-citation publication-type="journal" id="cit27"><name><surname>Castro</surname><given-names>D. J.</given-names></name>; <name><surname>Yu</surname><given-names>Z.</given-names></name>; <name><surname>Löhr</surname><given-names>C. V.</given-names></name>; <name><surname>Pereira</surname><given-names>C. B.</given-names></name>; <name><surname>Giovanini</surname><given-names>J. N.</given-names></name>; <name><surname>Fischer</surname><given-names>K. A.</given-names></name>; <name><surname>Orner</surname><given-names>G. A.</given-names></name>; <name><surname>Dashwood</surname><given-names>R. H.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name> (<year>2008</year>) <article-title>Chemoprevention
of dibenzo[<italic>a,l</italic>]pyrene transplacental carcinogenesis
in mice born to mothers administered green tea: primary role of caffeine</article-title>. <source>Carcinogenesis</source>
<volume>29</volume>, <fpage>1581</fpage>–<lpage>1586</lpage>.<pub-id pub-id-type="pmid">18635525</pub-id></mixed-citation>
              </ref>
              <ref id="ref28">
                <mixed-citation publication-type="journal" id="cit28"><name><surname>Castro</surname><given-names>D. J.</given-names></name>; <name><surname>Löhr</surname><given-names>C. V.</given-names></name>; <name><surname>Fischer</surname><given-names>K. A.</given-names></name>; <name><surname>Waters</surname><given-names>K. M.</given-names></name>; <name><surname>Webb-Robertson</surname><given-names>B. J.</given-names></name>; <name><surname>Dashwood</surname><given-names>R. H.</given-names></name>; <name><surname>Bailey</surname><given-names>G. S.</given-names></name>; <name><surname>Wiliams</surname><given-names>D. E.</given-names></name> (<year>2009</year>) <article-title>Identifying efficacious
approaches to chemoprevention with chlorophyllin, purified chlorophylls
and freeze-dried spinach in a mouse model of transplacental carcinogenesis</article-title>. <source>Carcinogenesis</source>
<volume>30</volume>, <fpage>315</fpage>–<lpage>320</lpage>.<pub-id pub-id-type="pmid">19073876</pub-id></mixed-citation>
              </ref>
              <ref id="ref29">
                <mixed-citation publication-type="journal" id="cit29"><name><surname>Shorey</surname><given-names>L. E.</given-names></name>; <name><surname>Castro</surname><given-names>D. J.</given-names></name>; <name><surname>Baird</surname><given-names>W. M.</given-names></name>; <name><surname>Siddens</surname><given-names>L. K.</given-names></name>; <name><surname>Löhr</surname><given-names>C. V.</given-names></name>; <name><surname>Matzke</surname><given-names>M. M.</given-names></name>; <name><surname>Waters</surname><given-names>K. M.</given-names></name>; <name><surname>Corley</surname><given-names>R. A.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name> (<year>2012</year>) <article-title>Transplacental
carcinogenesis with dibenzo[<italic>def,p</italic>]chrysene (DBC):
Timing of maternal exposures determines target tissue response in
offspring</article-title>. <source>Cancer Lett.</source>
<volume>317</volume>, <fpage>49</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">22085489</pub-id></mixed-citation>
              </ref>
              <ref id="ref30">
                <mixed-citation publication-type="journal" id="cit30"><name><surname>Yu</surname><given-names>Z.</given-names></name>; <name><surname>Loehr</surname><given-names>C.</given-names></name>; <name><surname>Fischer</surname><given-names>K. A.</given-names></name>; <name><surname>Louderback</surname><given-names>M.</given-names></name>; <name><surname>Krueger</surname><given-names>S. K.</given-names></name>; <name><surname>Dashwood</surname><given-names>R. H.</given-names></name>; <name><surname>Kerkvliet</surname><given-names>N. I.</given-names></name>; <name><surname>Pereira</surname><given-names>C. B.</given-names></name>; <name><surname>Jennings-Gee</surname><given-names>J.</given-names></name>; <name><surname>Dance</surname><given-names>S. T.</given-names></name>; <name><surname>Miller</surname><given-names>M. S.</given-names></name>; <name><surname>Bailey</surname><given-names>G. S.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name> (<year>2006</year>) <article-title><italic>In utero</italic> exposure
of mice to dibenzo[<italic>a,l</italic>]pyrene produces lymphoma in
the offspring: role of the aryl hydrocarbon receptor</article-title>. <source>Cancer Res.</source>
<volume>66</volume>, <fpage>755</fpage>–<lpage>762</lpage>.<pub-id pub-id-type="pmid">16424006</pub-id></mixed-citation>
              </ref>
              <ref id="ref31">
                <mixed-citation publication-type="journal" id="cit31"><name><surname>Yu</surname><given-names>Z.</given-names></name>; <name><surname>Mahadevan</surname><given-names>B.</given-names></name>; <name><surname>Löhr</surname><given-names>C. V.</given-names></name>; <name><surname>Fischer</surname><given-names>K. A.</given-names></name>; <name><surname>Louderback</surname><given-names>M. A.</given-names></name>; <name><surname>Krueger</surname><given-names>S. K.</given-names></name>; <name><surname>Pereira</surname><given-names>C. B.</given-names></name>; <name><surname>Albershardt</surname><given-names>D. J.</given-names></name>; <name><surname>Baird</surname><given-names>W. M.</given-names></name>; <name><surname>Bailey</surname><given-names>G. S.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name> (<year>2006</year>) <article-title>Indole-3-carbinol
in the maternal diet provides chemoprotection for the fetus against
transplacental carcinogenesis by the polycyclic aromatic hydrocarbon,
dibenzo[<italic>a,l</italic>]pyrene</article-title>. <source>Carcinogenesis</source>
<volume>27</volume>, <fpage>2116</fpage>–<lpage>2123</lpage>.<pub-id pub-id-type="pmid">16704990</pub-id></mixed-citation>
              </ref>
              <ref id="ref32">
                <mixed-citation publication-type="journal" id="cit32"><name><surname>BinSamat</surname><given-names>S.</given-names></name>; <name><surname>Green</surname><given-names>S.</given-names></name>; <name><surname>Beddoe</surname><given-names>A. H.</given-names></name> (<year>1997</year>) <article-title>The K-40
activity of one gram of
potassium</article-title>. <source>Phys. Med. Biol.</source>
<volume>42</volume>, <fpage>407</fpage>–<lpage>413</lpage>.<pub-id pub-id-type="pmid">9044422</pub-id></mixed-citation>
              </ref>
              <ref id="ref33">
                <mixed-citation publication-type="journal" id="cit33"><name><surname>Savarino</surname><given-names>V.</given-names></name>; <name><surname>Vigneri</surname><given-names>S.</given-names></name>; <name><surname>Celle</surname><given-names>G.</given-names></name> (<year>1999</year>) <article-title>The <sup>14</sup>C
urea breath test
in the diagnosis of <italic>Helicobacter pylori</italic> infection</article-title>. <source>Gut</source>
<volume>45</volume>, <fpage>118</fpage>–<lpage>122</lpage>.</mixed-citation>
              </ref>
              <ref id="ref34">
                <mixed-citation publication-type="undeclared" id="cit34">(<year>1997</year>) <article-title>Council Directive 97/43/Euratom
on Health Protection of Individuals
against the Dangers of Ionizing Radiation In</article-title>Relation
To<article-title>Medical Exposure, and Repealing Directive 84/466/Euratom</article-title>, Council of Federal Regulations 10 part 20.10003.</mixed-citation>
              </ref>
              <ref id="ref35">
                <mixed-citation publication-type="journal" id="cit35"><name><surname>Crowell</surname><given-names>S. R.</given-names></name>; <name><surname>Hanson-Drury</surname><given-names>S.</given-names></name>; <name><surname>Williams</surname><given-names>D. E.</given-names></name>; <name><surname>Corley</surname><given-names>R. A.</given-names></name> (<year>2014</year>) <article-title><italic>In vitro</italic> metabolism of benzo[<italic>a</italic>]pyrene and dibenzo[<italic>def,p</italic>]chrysene in rodent and human hepatic microsomes</article-title>. <source>Toxicol. Lett.</source>
<volume>228</volume>, <fpage>48</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">24769260</pub-id></mixed-citation>
              </ref>
              <ref id="ref36">
                <mixed-citation publication-type="journal" id="cit36"><name><surname>Ognibene</surname><given-names>T. J.</given-names></name>; <name><surname>Bench</surname><given-names>G.</given-names></name>; <name><surname>Vogel</surname><given-names>J. S.</given-names></name>; <name><surname>Peaslee</surname><given-names>G. F.</given-names></name>; <name><surname>Murov</surname><given-names>S.</given-names></name> (<year>2003</year>) <article-title>A high-throughput
method for the conversion of CO<sub>2</sub> obtained from biochemical
samples to graphite in septa-sealed vials for quantification of C-14
via accelerator mass spectrometry</article-title>. <source>Anal. Chem.</source>
<volume>75</volume>, <fpage>2192</fpage>–<lpage>2196</lpage>.<pub-id pub-id-type="pmid">12720362</pub-id></mixed-citation>
              </ref>
              <ref id="ref37">
                <mixed-citation publication-type="journal" id="cit37"><name><surname>Ognibene</surname><given-names>T. J.</given-names></name>; <name><surname>Bench</surname><given-names>G.</given-names></name>; <name><surname>Brown</surname><given-names>T. A.</given-names></name>; <name><surname>Vogel</surname><given-names>J. S.</given-names></name> (<year>2004</year>) <article-title>The LLNL accelerator
mass spectrometry system for biochemical <sup>14</sup>C-measurements</article-title>. <source>Nucl. Instrum. Methods Phys. Res.</source>
<volume>23</volume>, <fpage>12</fpage>–<lpage>15</lpage>.</mixed-citation>
              </ref>
              <ref id="ref38">
                <mixed-citation publication-type="journal" id="cit38"><name><surname>Ognibene</surname><given-names>T. J.</given-names></name>; <name><surname>Salazar</surname><given-names>G. A.</given-names></name> (<year>2013</year>) <article-title>Installation of hybrid ion source on the 1-MV LLNL
BioAMS spectrometer</article-title>. <source>Nucl. Instrum. Methods
Phys. Res., Sect. B</source>
<volume>294</volume>, <fpage>311</fpage>–<lpage>314</lpage>.<pub-id pub-id-type="pmid">23467295</pub-id></mixed-citation>
              </ref>
              <ref id="ref39">
                <mixed-citation publication-type="book" id="cit39"><person-group person-group-type="allauthors"><name><surname>Usansky</surname><given-names>J.</given-names></name>, <name><surname>Desai</surname><given-names>A.</given-names></name>, and <name><surname>Tang-Liu</surname><given-names>D.</given-names></name></person-group> (<year>2005</year>) <source>PK Functions for
Microsoft Excel</source>, <publisher-name>Department of Pharmacokinetics
and Drug Metabolism, Allergan</publisher-name>, <publisher-loc>Irvine,
CA</publisher-loc>.</mixed-citation>
              </ref>
              <ref id="ref40">
                <mixed-citation publication-type="journal" id="cit40"><name><surname>Gibaldi</surname><given-names>M.</given-names></name>; <name><surname>Perrier</surname><given-names>D.</given-names></name> (<year>1982</year>) <article-title>Noncompartmental analysis
based on statistical moment
theory</article-title>. <source>Pharmacokin</source>
<volume>2</volume>, <fpage>409</fpage>–<lpage>417</lpage>.</mixed-citation>
              </ref>
              <ref id="ref41">
                <mixed-citation publication-type="journal" id="cit41"><name><surname>Rahman</surname><given-names>A.</given-names></name>; <name><surname>Barrowman</surname><given-names>J. A.</given-names></name>; <name><surname>Rahimtula</surname><given-names>A.</given-names></name> (<year>1986</year>) <article-title>The influence
of bile on the availability
of polynuclear aromatic hydrocarbons from the rat intestine</article-title>. <source>Can. J. Physiol. Pharmacol.</source>
<volume>64</volume>, <fpage>1214</fpage>–<lpage>1218</lpage>.<pub-id pub-id-type="pmid">3096546</pub-id></mixed-citation>
              </ref>
              <ref id="ref42">
                <mixed-citation publication-type="journal" id="cit42"><name><surname>Harris</surname><given-names>D. L.</given-names></name>; <name><surname>Hood</surname><given-names>D. B.</given-names></name>; <name><surname>Ramesh</surname><given-names>A.</given-names></name> (<year>2008</year>) <article-title>Vehicle-dependent disposition kinetics
of fluoranthene in Fisher-344 rats</article-title>. <source>Int. J.
Environm. Res. Public Health</source>
<volume>5</volume>, <fpage>41</fpage>–<lpage>48</lpage>.</mixed-citation>
              </ref>
              <ref id="ref43">
                <mixed-citation publication-type="journal" id="cit43"><name><surname>Jongeneelen</surname><given-names>F. J.</given-names></name>; <name><surname>Leijdekkers</surname><given-names>C. M.</given-names></name>; <name><surname>Henderson</surname><given-names>P. T.</given-names></name> (<year>1984</year>) <article-title>Urinary-excretion of 3-hydroxy-benzo[<italic>a</italic>]pyrene after percutaneous penetration and oral absorption
of benzo[<italic>a</italic>]pyrene in rats</article-title>. <source>Cancer Lett.</source>
<volume>25</volume>, <fpage>195</fpage>–<lpage>201</lpage>.<pub-id pub-id-type="pmid">6509438</pub-id></mixed-citation>
              </ref>
              <ref id="ref44">
                <mixed-citation publication-type="journal" id="cit44"><name><surname>Bouchard</surname><given-names>M.</given-names></name>; <name><surname>Viau</surname><given-names>C.</given-names></name> (<year>1997</year>) <article-title>Urinary excretion of
benzo[<italic>a</italic>] pyrene metabolites
following intravenous, oral, and cutaneous benzo[<italic>a</italic>]pyrene administration</article-title>. <source>Can. J. Physiol. Pharmacol.</source>
<volume>75</volume>, <fpage>185</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">9164700</pub-id></mixed-citation>
              </ref>
              <ref id="ref45">
                <mixed-citation publication-type="journal" id="cit45"><name><surname>Baird</surname><given-names>W. M.</given-names></name>; <name><surname>Hooven</surname><given-names>L. A.</given-names></name>; <name><surname>Mahadevan</surname><given-names>B.</given-names></name> (<year>2005</year>) <article-title>Carcinogenic
polycyclic aromatic
hydrocarbon-DNA adducts and mechanism of action</article-title>. <source>Environm. Mol. Mutagen.</source>
<volume>45</volume>, <fpage>106</fpage>–<lpage>114</lpage>.</mixed-citation>
              </ref>
              <ref id="ref46">
                <mixed-citation publication-type="journal" id="cit46"><name><surname>Shimada</surname><given-names>T.</given-names></name> (<year>2006</year>) <article-title>Xenobiotic-metabolizing
enzymes involved in activation and detoxication of carcinogenic polycyclic
aromatic hydrocarbons</article-title>. <source>Drug Metabol. Pharmacokinet.</source>
<volume>21</volume>, <fpage>257</fpage>–<lpage>276</lpage>.</mixed-citation>
              </ref>
              <ref id="ref47">
                <mixed-citation publication-type="journal" id="cit47"><name><surname>Mahadevan</surname><given-names>B.</given-names></name>; <name><surname>Dashwood</surname><given-names>W.-M.</given-names></name>; <name><surname>Luch</surname><given-names>A.</given-names></name>; <name><surname>Pecaj</surname><given-names>A.</given-names></name>; <name><surname>Doehmer</surname><given-names>J.</given-names></name>; <name><surname>Seidel</surname><given-names>A.</given-names></name>; <name><surname>Pereira</surname><given-names>C.</given-names></name>; <name><surname>Baird</surname><given-names>W. M.</given-names></name> (<year>2003</year>) <article-title>Mutations induced
by (−)-<italic>anti</italic>-11<italic>R</italic>,12<italic>S</italic>-dihydrodiol-13<italic>S</italic>,14<italic>R</italic>-epoxide
of dibenzo[<italic>a,l</italic>]pyrene in the coding region of the
hypoxanthine phosphoribosyltransferase (Hprt) gene in Chinese hamster
V79 cells</article-title>. <source>Environ. Mol. Mutagen.</source>
<volume>41</volume>, <fpage>131</fpage>–<lpage>139</lpage>.<pub-id pub-id-type="pmid">12605383</pub-id></mixed-citation>
              </ref>
              <ref id="ref48">
                <mixed-citation publication-type="journal" id="cit48"><name><surname>Thomas</surname><given-names>A. T.</given-names></name>; <name><surname>Stewart</surname><given-names>B. J.</given-names></name>; <name><surname>Ognibene</surname><given-names>T. J.</given-names></name>; <name><surname>Turteltaub</surname><given-names>K. W.</given-names></name>; <name><surname>Bench</surname><given-names>G.</given-names></name> (<year>2013</year>) <article-title>Directly coupled high-performance
liquid chromatography-accelerator
mass spectrometry measurement of chemically modified protein and peptides</article-title>. <source>Anal. Chem.</source>
<volume>85</volume>, <fpage>3644</fpage>–<lpage>3650</lpage>.<pub-id pub-id-type="pmid">23413773</pub-id></mixed-citation>
              </ref>
              <ref id="ref49">
                <mixed-citation publication-type="journal" id="cit49"><name><surname>Zhong</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Carmella</surname><given-names>S. G.</given-names></name>; <name><surname>Hochalter</surname><given-names>J. B.</given-names></name>; <name><surname>Rauch</surname><given-names>D.</given-names></name>; <name><surname>Oliver</surname><given-names>A.</given-names></name>; <name><surname>Jensen</surname><given-names>J.</given-names></name>; <name><surname>Hatsukami</surname><given-names>D. K.</given-names></name>; <name><surname>Upadhyaya</surname><given-names>P.</given-names></name>; <name><surname>Zimmerman</surname><given-names>C.</given-names></name>; <name><surname>Hecht</surname><given-names>S. S.</given-names></name> (<year>2011</year>) <article-title>Metabolism of [D<sub>10</sub>]phenanthrene to tetraols in smokers for potential lung cancer
susceptibility assessment: comparison of oral and inhalation routes
of administration</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>338</volume>, <fpage>353</fpage>–<lpage>361</lpage>.<pub-id pub-id-type="pmid">21515812</pub-id></mixed-citation>
              </ref>
              <ref id="ref50">
                <mixed-citation publication-type="journal" id="cit50"><name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Zhong</surname><given-names>Y.</given-names></name>; <name><surname>Carmella</surname><given-names>S. G.</given-names></name>; <name><surname>Hochalter</surname><given-names>J. B.</given-names></name>; <name><surname>Rauch</surname><given-names>D.</given-names></name>; <name><surname>Oliver</surname><given-names>A.</given-names></name>; <name><surname>Jensen</surname><given-names>J.</given-names></name>; <name><surname>Hatsukami</surname><given-names>D. K.</given-names></name>; <name><surname>Upadhyaya</surname><given-names>P.</given-names></name>; <name><surname>Hecht</surname><given-names>S. S.</given-names></name>; <name><surname>Zimmerman</surname><given-names>C. L.</given-names></name> (<year>2012</year>) <article-title>Phenanthrene
metabolism in smokers: use of a two-step diagnostic plot approach
to identify subjects with extensive metabolic activation</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>342</volume>, <fpage>750</fpage>–<lpage>760</lpage>.<pub-id pub-id-type="pmid">22674470</pub-id></mixed-citation>
              </ref>
              <ref id="ref51">
                <mixed-citation publication-type="journal" id="cit51"><name><surname>Hecht</surname><given-names>S. S.</given-names></name>; <name><surname>Hochalter</surname><given-names>J. B.</given-names></name>; <name><surname>Carmella</surname><given-names>S. G.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Rauch</surname><given-names>D. M.</given-names></name>; <name><surname>Fujioka</surname><given-names>N.</given-names></name>; <name><surname>Nensen</surname><given-names>J.</given-names></name>; <name><surname>Hatsukami</surname><given-names>D. K.</given-names></name> (<year>2013</year>) <article-title>Longitudinal
study of [D<sub>10</sub>]phenanthrene metabolism by the diol epoxide
pathway in smokers</article-title>. <source>Biomarkers</source>
<volume>18</volume>, <fpage>144</fpage>–<lpage>150</lpage>.<pub-id pub-id-type="pmid">23336104</pub-id></mixed-citation>
              </ref>
              <ref id="ref52">
                <mixed-citation publication-type="journal" id="cit52"><name><surname>Hecht</surname><given-names>S. S.</given-names></name>; <name><surname>Carmella</surname><given-names>S. G.</given-names></name>; <name><surname>Villalta</surname><given-names>P. W.</given-names></name>; <name><surname>Hochalter</surname><given-names>J. B.</given-names></name> (<year>2010</year>) <article-title>Analysis
of phenanthrene and benzo[<italic>a</italic>]pyrene tetraol enantiomers
in human urine: relevance to the bay region diol epoxide hypothesis
of benzo[<italic>a</italic>]pyrene carcinogenesis and to biomarker
studies</article-title>. <source>Chem. Res. Toxicol.</source>
<volume>23</volume>, <fpage>900</fpage>–<lpage>908</lpage>.<pub-id pub-id-type="pmid">20369855</pub-id></mixed-citation>
              </ref>
              <ref id="ref53">
                <mixed-citation publication-type="patent" id="cit53"><collab>U.S. EPA</collab> (<year>2010</year>) Development of a Relative
Potency
Factor (RPF) Approach for Polycyclic Aromatic Hydrocarbon (PAH) Mixtures
(External Review Draft), <patent>EPA/635/R-08/012A</patent>, U.S. EPA, Washington,
D.C.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
